CN1670201A - Fumaric reductase Ip subunit of liver fluke, its coding acid and application - Google Patents
Fumaric reductase Ip subunit of liver fluke, its coding acid and application Download PDFInfo
- Publication number
- CN1670201A CN1670201A CN 200510024006 CN200510024006A CN1670201A CN 1670201 A CN1670201 A CN 1670201A CN 200510024006 CN200510024006 CN 200510024006 CN 200510024006 A CN200510024006 A CN 200510024006A CN 1670201 A CN1670201 A CN 1670201A
- Authority
- CN
- China
- Prior art keywords
- subunit
- polynucleotide
- succinodehydrogenase
- liver fluke
- polypeptide
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 208000006275 fascioliasis Diseases 0.000 title claims description 122
- 241000242711 Fasciola hepatica Species 0.000 title claims description 116
- 239000002253 acid Substances 0.000 title description 4
- 108090000765 processed proteins & peptides Proteins 0.000 claims abstract description 94
- 108091033319 polynucleotide Proteins 0.000 claims abstract description 91
- 239000002157 polynucleotide Substances 0.000 claims abstract description 91
- 102000040430 polynucleotide Human genes 0.000 claims abstract description 91
- 229920001184 polypeptide Polymers 0.000 claims abstract description 87
- 102000004196 processed proteins & peptides Human genes 0.000 claims abstract description 87
- 108090000623 proteins and genes Proteins 0.000 claims abstract description 61
- 239000000523 sample Substances 0.000 claims abstract description 54
- 229960005486 vaccine Drugs 0.000 claims abstract description 10
- 238000009396 hybridization Methods 0.000 claims description 30
- 239000012634 fragment Substances 0.000 claims description 28
- 108091032973 (ribonucleotides)n+m Proteins 0.000 claims description 26
- 230000014509 gene expression Effects 0.000 claims description 21
- 150000007523 nucleic acids Chemical class 0.000 claims description 19
- 238000006243 chemical reaction Methods 0.000 claims description 17
- 238000012360 testing method Methods 0.000 claims description 17
- 230000000295 complement effect Effects 0.000 claims description 15
- 102000039446 nucleic acids Human genes 0.000 claims description 13
- 108020004707 nucleic acids Proteins 0.000 claims description 13
- 239000003112 inhibitor Substances 0.000 claims description 10
- 230000003321 amplification Effects 0.000 claims description 8
- 238000003199 nucleic acid amplification method Methods 0.000 claims description 8
- 230000000692 anti-sense effect Effects 0.000 claims description 6
- 238000002493 microarray Methods 0.000 claims description 5
- 102000040650 (ribonucleotides)n+m Human genes 0.000 claims description 3
- 238000011895 specific detection Methods 0.000 claims description 3
- 125000003275 alpha amino acid group Chemical group 0.000 claims 2
- 238000006384 oligomerization reaction Methods 0.000 claims 1
- 230000001105 regulatory effect Effects 0.000 claims 1
- 102000019259 Succinate Dehydrogenase Human genes 0.000 abstract description 14
- 108010012901 Succinate Dehydrogenase Proteins 0.000 abstract description 14
- 239000003153 chemical reaction reagent Substances 0.000 abstract description 10
- 238000012216 screening Methods 0.000 abstract description 9
- 238000003745 diagnosis Methods 0.000 abstract description 8
- 206010009344 Clonorchiasis Diseases 0.000 abstract description 3
- 238000000034 method Methods 0.000 description 63
- 108020004414 DNA Proteins 0.000 description 40
- 210000004027 cell Anatomy 0.000 description 30
- 238000005516 engineering process Methods 0.000 description 27
- 239000002299 complementary DNA Substances 0.000 description 26
- ROHFNLRQFUQHCH-YFKPBYRVSA-N L-leucine Chemical compound CC(C)C[C@H](N)C(O)=O ROHFNLRQFUQHCH-YFKPBYRVSA-N 0.000 description 24
- 150000001413 amino acids Chemical class 0.000 description 24
- 239000002773 nucleotide Substances 0.000 description 23
- 125000003729 nucleotide group Chemical group 0.000 description 23
- 102000004169 proteins and genes Human genes 0.000 description 23
- 235000018102 proteins Nutrition 0.000 description 19
- 239000000047 product Substances 0.000 description 18
- 108091028043 Nucleic acid sequence Proteins 0.000 description 17
- 239000000427 antigen Substances 0.000 description 17
- 102000036639 antigens Human genes 0.000 description 17
- 108091007433 antigens Proteins 0.000 description 17
- 230000000694 effects Effects 0.000 description 16
- AGPKZVBTJJNPAG-WHFBIAKZSA-N L-isoleucine Chemical compound CC[C@H](C)[C@H](N)C(O)=O AGPKZVBTJJNPAG-WHFBIAKZSA-N 0.000 description 15
- 239000000243 solution Substances 0.000 description 15
- DHMQDGOQFOQNFH-UHFFFAOYSA-N Glycine Chemical compound NCC(O)=O DHMQDGOQFOQNFH-UHFFFAOYSA-N 0.000 description 14
- 210000001519 tissue Anatomy 0.000 description 14
- 238000003752 polymerase chain reaction Methods 0.000 description 13
- PCHJSUWPFVWCPO-UHFFFAOYSA-N gold Chemical compound [Au] PCHJSUWPFVWCPO-UHFFFAOYSA-N 0.000 description 12
- 241000894006 Bacteria Species 0.000 description 11
- 238000001514 detection method Methods 0.000 description 11
- 239000013604 expression vector Substances 0.000 description 11
- 125000001360 methionine group Chemical group N[C@@H](CCSC)C(=O)* 0.000 description 11
- 239000013612 plasmid Substances 0.000 description 11
- 239000000203 mixture Substances 0.000 description 10
- 235000001014 amino acid Nutrition 0.000 description 9
- 229940024606 amino acid Drugs 0.000 description 9
- 108020004999 messenger RNA Proteins 0.000 description 9
- 238000002360 preparation method Methods 0.000 description 9
- 241001327942 Clonorchis Species 0.000 description 8
- 102000004190 Enzymes Human genes 0.000 description 8
- 108090000790 Enzymes Proteins 0.000 description 8
- 150000001875 compounds Chemical class 0.000 description 8
- 230000008521 reorganization Effects 0.000 description 8
- 238000000926 separation method Methods 0.000 description 8
- 108091026890 Coding region Proteins 0.000 description 7
- 125000000539 amino acid group Chemical group 0.000 description 7
- 230000008859 change Effects 0.000 description 7
- 230000006870 function Effects 0.000 description 7
- 210000002966 serum Anatomy 0.000 description 7
- 210000001550 testis Anatomy 0.000 description 7
- 238000002965 ELISA Methods 0.000 description 6
- ISWSIDIOOBJBQZ-UHFFFAOYSA-N Phenol Chemical compound OC1=CC=CC=C1 ISWSIDIOOBJBQZ-UHFFFAOYSA-N 0.000 description 6
- 239000002671 adjuvant Substances 0.000 description 6
- 210000000013 bile duct Anatomy 0.000 description 6
- 238000002474 experimental method Methods 0.000 description 6
- 230000036039 immunity Effects 0.000 description 6
- 208000015181 infectious disease Diseases 0.000 description 6
- 238000004519 manufacturing process Methods 0.000 description 6
- 239000000463 material Substances 0.000 description 6
- 238000000746 purification Methods 0.000 description 6
- 230000002285 radioactive effect Effects 0.000 description 6
- 230000028327 secretion Effects 0.000 description 6
- 108091034117 Oligonucleotide Proteins 0.000 description 5
- 241000283973 Oryctolagus cuniculus Species 0.000 description 5
- 230000000890 antigenic effect Effects 0.000 description 5
- 239000002585 base Substances 0.000 description 5
- 230000004071 biological effect Effects 0.000 description 5
- 230000001276 controlling effect Effects 0.000 description 5
- 238000001962 electrophoresis Methods 0.000 description 5
- 230000001900 immune effect Effects 0.000 description 5
- 239000007788 liquid Substances 0.000 description 5
- 239000003550 marker Substances 0.000 description 5
- 230000008569 process Effects 0.000 description 5
- 230000004044 response Effects 0.000 description 5
- 108091092562 ribozyme Proteins 0.000 description 5
- 239000013598 vector Substances 0.000 description 5
- 108090000994 Catalytic RNA Proteins 0.000 description 4
- 102000053642 Catalytic RNA Human genes 0.000 description 4
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 4
- VZCYOOQTPOCHFL-OWOJBTEDSA-N Fumaric acid Chemical compound OC(=O)\C=C\C(O)=O VZCYOOQTPOCHFL-OWOJBTEDSA-N 0.000 description 4
- 241001465754 Metazoa Species 0.000 description 4
- 238000010521 absorption reaction Methods 0.000 description 4
- 239000005557 antagonist Substances 0.000 description 4
- 230000008827 biological function Effects 0.000 description 4
- 230000015572 biosynthetic process Effects 0.000 description 4
- 238000006555 catalytic reaction Methods 0.000 description 4
- 230000002759 chromosomal effect Effects 0.000 description 4
- 210000003527 eukaryotic cell Anatomy 0.000 description 4
- 239000000284 extract Substances 0.000 description 4
- 239000012530 fluid Substances 0.000 description 4
- 239000003365 glass fiber Substances 0.000 description 4
- 230000003053 immunization Effects 0.000 description 4
- 230000005764 inhibitory process Effects 0.000 description 4
- 210000004962 mammalian cell Anatomy 0.000 description 4
- 238000010369 molecular cloning Methods 0.000 description 4
- 238000001556 precipitation Methods 0.000 description 4
- 239000000126 substance Substances 0.000 description 4
- 241001327965 Clonorchis sinensis Species 0.000 description 3
- 241000238631 Hexapoda Species 0.000 description 3
- 206010027336 Menstruation delayed Diseases 0.000 description 3
- 239000000020 Nitrocellulose Substances 0.000 description 3
- 238000000636 Northern blotting Methods 0.000 description 3
- 108700026244 Open Reading Frames Proteins 0.000 description 3
- 102000004316 Oxidoreductases Human genes 0.000 description 3
- 108090000854 Oxidoreductases Proteins 0.000 description 3
- 108020005091 Replication Origin Proteins 0.000 description 3
- 240000004808 Saccharomyces cerevisiae Species 0.000 description 3
- 241000700605 Viruses Species 0.000 description 3
- 238000003556 assay Methods 0.000 description 3
- 230000001580 bacterial effect Effects 0.000 description 3
- 230000023852 carbohydrate metabolic process Effects 0.000 description 3
- 235000021256 carbohydrate metabolism Nutrition 0.000 description 3
- 150000001720 carbohydrates Chemical class 0.000 description 3
- 235000014633 carbohydrates Nutrition 0.000 description 3
- 239000003795 chemical substances by application Substances 0.000 description 3
- 238000004587 chromatography analysis Methods 0.000 description 3
- 210000000349 chromosome Anatomy 0.000 description 3
- KRKNYBCHXYNGOX-UHFFFAOYSA-N citric acid Chemical compound OC(=O)CC(O)(C(O)=O)CC(O)=O KRKNYBCHXYNGOX-UHFFFAOYSA-N 0.000 description 3
- 239000002131 composite material Substances 0.000 description 3
- 238000013016 damping Methods 0.000 description 3
- 230000008034 disappearance Effects 0.000 description 3
- 201000010099 disease Diseases 0.000 description 3
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 3
- 230000037149 energy metabolism Effects 0.000 description 3
- 210000004754 hybrid cell Anatomy 0.000 description 3
- 238000007901 in situ hybridization Methods 0.000 description 3
- 238000003780 insertion Methods 0.000 description 3
- 230000037431 insertion Effects 0.000 description 3
- 230000000968 intestinal effect Effects 0.000 description 3
- 239000002502 liposome Substances 0.000 description 3
- 239000012528 membrane Substances 0.000 description 3
- VNWKTOKETHGBQD-UHFFFAOYSA-N methane Natural products C VNWKTOKETHGBQD-UHFFFAOYSA-N 0.000 description 3
- 210000004400 mucous membrane Anatomy 0.000 description 3
- 229920001220 nitrocellulos Polymers 0.000 description 3
- 238000012856 packing Methods 0.000 description 3
- 229920003023 plastic Polymers 0.000 description 3
- 239000004033 plastic Substances 0.000 description 3
- 210000001236 prokaryotic cell Anatomy 0.000 description 3
- 238000011160 research Methods 0.000 description 3
- 108091008146 restriction endonucleases Proteins 0.000 description 3
- 238000010839 reverse transcription Methods 0.000 description 3
- 238000003757 reverse transcription PCR Methods 0.000 description 3
- 238000002415 sodium dodecyl sulfate polyacrylamide gel electrophoresis Methods 0.000 description 3
- 239000000758 substrate Substances 0.000 description 3
- 238000013518 transcription Methods 0.000 description 3
- 230000035897 transcription Effects 0.000 description 3
- 238000005406 washing Methods 0.000 description 3
- 206010063659 Aversion Diseases 0.000 description 2
- UXVMQQNJUSDDNG-UHFFFAOYSA-L Calcium chloride Chemical compound [Cl-].[Cl-].[Ca+2] UXVMQQNJUSDDNG-UHFFFAOYSA-L 0.000 description 2
- HEDRZPFGACZZDS-UHFFFAOYSA-N Chloroform Chemical compound ClC(Cl)Cl HEDRZPFGACZZDS-UHFFFAOYSA-N 0.000 description 2
- 108091033380 Coding strand Proteins 0.000 description 2
- 230000004544 DNA amplification Effects 0.000 description 2
- 102000004163 DNA-directed RNA polymerases Human genes 0.000 description 2
- 108090000626 DNA-directed RNA polymerases Proteins 0.000 description 2
- 101710088194 Dehydrogenase Proteins 0.000 description 2
- 241000588724 Escherichia coli Species 0.000 description 2
- LYCAIKOWRPUZTN-UHFFFAOYSA-N Ethylene glycol Chemical compound OCCO LYCAIKOWRPUZTN-UHFFFAOYSA-N 0.000 description 2
- 108091060211 Expressed sequence tag Proteins 0.000 description 2
- 108010043121 Green Fluorescent Proteins Proteins 0.000 description 2
- 102000004144 Green Fluorescent Proteins Human genes 0.000 description 2
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 2
- 206010061218 Inflammation Diseases 0.000 description 2
- ROHFNLRQFUQHCH-UHFFFAOYSA-N Leucine Natural products CC(C)CC(N)C(O)=O ROHFNLRQFUQHCH-UHFFFAOYSA-N 0.000 description 2
- 238000012408 PCR amplification Methods 0.000 description 2
- 229920001213 Polysorbate 20 Polymers 0.000 description 2
- 108091034057 RNA (poly(A)) Proteins 0.000 description 2
- 108020004511 Recombinant DNA Proteins 0.000 description 2
- 108091081021 Sense strand Proteins 0.000 description 2
- 229920002684 Sepharose Polymers 0.000 description 2
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 2
- 238000002105 Southern blotting Methods 0.000 description 2
- 206010052428 Wound Diseases 0.000 description 2
- 208000027418 Wounds and injury Diseases 0.000 description 2
- 238000004458 analytical method Methods 0.000 description 2
- 230000007503 antigenic stimulation Effects 0.000 description 2
- 210000000941 bile Anatomy 0.000 description 2
- 230000027455 binding Effects 0.000 description 2
- 238000001574 biopsy Methods 0.000 description 2
- 239000001110 calcium chloride Substances 0.000 description 2
- 229910001628 calcium chloride Inorganic materials 0.000 description 2
- 244000309466 calf Species 0.000 description 2
- 239000002775 capsule Substances 0.000 description 2
- 230000010261 cell growth Effects 0.000 description 2
- 238000007385 chemical modification Methods 0.000 description 2
- 230000014107 chromosome localization Effects 0.000 description 2
- 230000009514 concussion Effects 0.000 description 2
- 238000013461 design Methods 0.000 description 2
- 230000029087 digestion Effects 0.000 description 2
- 238000009826 distribution Methods 0.000 description 2
- 239000003814 drug Substances 0.000 description 2
- 239000003596 drug target Substances 0.000 description 2
- 238000001035 drying Methods 0.000 description 2
- 238000004520 electroporation Methods 0.000 description 2
- 230000002708 enhancing effect Effects 0.000 description 2
- 210000002919 epithelial cell Anatomy 0.000 description 2
- 239000001530 fumaric acid Substances 0.000 description 2
- 238000001502 gel electrophoresis Methods 0.000 description 2
- 230000002068 genetic effect Effects 0.000 description 2
- 239000005090 green fluorescent protein Substances 0.000 description 2
- 235000014304 histidine Nutrition 0.000 description 2
- 238000002649 immunization Methods 0.000 description 2
- 230000036046 immunoreaction Effects 0.000 description 2
- 230000004054 inflammatory process Effects 0.000 description 2
- 230000002452 interceptive effect Effects 0.000 description 2
- 238000001155 isoelectric focusing Methods 0.000 description 2
- 150000002632 lipids Chemical class 0.000 description 2
- 238000004811 liquid chromatography Methods 0.000 description 2
- 210000004185 liver Anatomy 0.000 description 2
- 210000005229 liver cell Anatomy 0.000 description 2
- 238000002156 mixing Methods 0.000 description 2
- 230000035772 mutation Effects 0.000 description 2
- 230000009871 nonspecific binding Effects 0.000 description 2
- 230000001575 pathological effect Effects 0.000 description 2
- 210000005259 peripheral blood Anatomy 0.000 description 2
- 239000011886 peripheral blood Substances 0.000 description 2
- 230000035790 physiological processes and functions Effects 0.000 description 2
- 229920002401 polyacrylamide Polymers 0.000 description 2
- -1 polyoxyethylene Polymers 0.000 description 2
- 239000000256 polyoxyethylene sorbitan monolaurate Substances 0.000 description 2
- BWHMMNNQKKPAPP-UHFFFAOYSA-L potassium carbonate Chemical compound [K+].[K+].[O-]C([O-])=O BWHMMNNQKKPAPP-UHFFFAOYSA-L 0.000 description 2
- 238000003259 recombinant expression Methods 0.000 description 2
- 229940126583 recombinant protein vaccine Drugs 0.000 description 2
- 230000002787 reinforcement Effects 0.000 description 2
- GHMLBKRAJCXXBS-UHFFFAOYSA-N resorcinol Chemical compound OC1=CC=CC(O)=C1 GHMLBKRAJCXXBS-UHFFFAOYSA-N 0.000 description 2
- 230000002441 reversible effect Effects 0.000 description 2
- 150000003839 salts Chemical class 0.000 description 2
- 238000007789 sealing Methods 0.000 description 2
- 230000003248 secreting effect Effects 0.000 description 2
- 238000012772 sequence design Methods 0.000 description 2
- 238000012882 sequential analysis Methods 0.000 description 2
- 238000002791 soaking Methods 0.000 description 2
- 239000011734 sodium Substances 0.000 description 2
- 229910052708 sodium Inorganic materials 0.000 description 2
- 239000007787 solid Substances 0.000 description 2
- 239000007790 solid phase Substances 0.000 description 2
- 230000002269 spontaneous effect Effects 0.000 description 2
- 231100000331 toxic Toxicity 0.000 description 2
- 230000002588 toxic effect Effects 0.000 description 2
- VZCYOOQTPOCHFL-UHFFFAOYSA-N trans-butenedioic acid Natural products OC(=O)C=CC(O)=O VZCYOOQTPOCHFL-UHFFFAOYSA-N 0.000 description 2
- 238000010361 transduction Methods 0.000 description 2
- 230000026683 transduction Effects 0.000 description 2
- 238000001890 transfection Methods 0.000 description 2
- 230000009466 transformation Effects 0.000 description 2
- 229910021642 ultra pure water Inorganic materials 0.000 description 2
- 239000012498 ultrapure water Substances 0.000 description 2
- 241000701161 unidentified adenovirus Species 0.000 description 2
- 241001430294 unidentified retrovirus Species 0.000 description 2
- 235000013311 vegetables Nutrition 0.000 description 2
- 210000005253 yeast cell Anatomy 0.000 description 2
- NWXMGUDVXFXRIG-WESIUVDSSA-N (4s,4as,5as,6s,12ar)-4-(dimethylamino)-1,6,10,11,12a-pentahydroxy-6-methyl-3,12-dioxo-4,4a,5,5a-tetrahydrotetracene-2-carboxamide Chemical compound C1=CC=C2[C@](O)(C)[C@H]3C[C@H]4[C@H](N(C)C)C(=O)C(C(N)=O)=C(O)[C@@]4(O)C(=O)C3=C(O)C2=C1O NWXMGUDVXFXRIG-WESIUVDSSA-N 0.000 description 1
- UZGKAASZIMOAMU-UHFFFAOYSA-N 124177-85-1 Chemical compound NP(=O)=O UZGKAASZIMOAMU-UHFFFAOYSA-N 0.000 description 1
- QKNYBSVHEMOAJP-UHFFFAOYSA-N 2-amino-2-(hydroxymethyl)propane-1,3-diol;hydron;chloride Chemical compound Cl.OCC(N)(CO)CO QKNYBSVHEMOAJP-UHFFFAOYSA-N 0.000 description 1
- DVLFYONBTKHTER-UHFFFAOYSA-N 3-(N-morpholino)propanesulfonic acid Chemical compound OS(=O)(=O)CCCN1CCOCC1 DVLFYONBTKHTER-UHFFFAOYSA-N 0.000 description 1
- FRXSZNDVFUDTIR-UHFFFAOYSA-N 6-methoxy-1,2,3,4-tetrahydroquinoline Chemical compound N1CCCC2=CC(OC)=CC=C21 FRXSZNDVFUDTIR-UHFFFAOYSA-N 0.000 description 1
- 102000007469 Actins Human genes 0.000 description 1
- 108010085238 Actins Proteins 0.000 description 1
- 229920000936 Agarose Polymers 0.000 description 1
- 102000009027 Albumins Human genes 0.000 description 1
- 108010088751 Albumins Proteins 0.000 description 1
- 102000002260 Alkaline Phosphatase Human genes 0.000 description 1
- 108020004774 Alkaline Phosphatase Proteins 0.000 description 1
- 108020004491 Antisense DNA Proteins 0.000 description 1
- 108020005544 Antisense RNA Proteins 0.000 description 1
- 206010003445 Ascites Diseases 0.000 description 1
- 206010003694 Atrophy Diseases 0.000 description 1
- 241000972773 Aulopiformes Species 0.000 description 1
- 206010056375 Bile duct obstruction Diseases 0.000 description 1
- 241000283707 Capra Species 0.000 description 1
- BVKZGUZCCUSVTD-UHFFFAOYSA-L Carbonate Chemical compound [O-]C([O-])=O BVKZGUZCCUSVTD-UHFFFAOYSA-L 0.000 description 1
- 239000005746 Carboxin Substances 0.000 description 1
- KZBUYRJDOAKODT-UHFFFAOYSA-N Chlorine Chemical compound ClCl KZBUYRJDOAKODT-UHFFFAOYSA-N 0.000 description 1
- 206010008635 Cholestasis Diseases 0.000 description 1
- 108020004705 Codon Proteins 0.000 description 1
- ACTIUHUUMQJHFO-UHFFFAOYSA-N Coenzym Q10 Natural products COC1=C(OC)C(=O)C(CC=C(C)CCC=C(C)CCC=C(C)CCC=C(C)CCC=C(C)CCC=C(C)CCC=C(C)CCC=C(C)CCC=C(C)CCC=C(C)C)=C(C)C1=O ACTIUHUUMQJHFO-UHFFFAOYSA-N 0.000 description 1
- 108020004635 Complementary DNA Proteins 0.000 description 1
- 102000053602 DNA Human genes 0.000 description 1
- 238000000018 DNA microarray Methods 0.000 description 1
- 102000016928 DNA-directed DNA polymerase Human genes 0.000 description 1
- 108010014303 DNA-directed DNA polymerase Proteins 0.000 description 1
- 238000009007 Diagnostic Kit Methods 0.000 description 1
- 102000002322 Egg Proteins Human genes 0.000 description 1
- 108010000912 Egg Proteins Proteins 0.000 description 1
- 241000196324 Embryophyta Species 0.000 description 1
- 108010042407 Endonucleases Proteins 0.000 description 1
- 102000004533 Endonucleases Human genes 0.000 description 1
- 241000305071 Enterobacterales Species 0.000 description 1
- 108010013369 Enteropeptidase Proteins 0.000 description 1
- 241000206602 Eukaryota Species 0.000 description 1
- 229920001917 Ficoll Polymers 0.000 description 1
- 102000003983 Flavoproteins Human genes 0.000 description 1
- 108010057573 Flavoproteins Proteins 0.000 description 1
- 241000233866 Fungi Species 0.000 description 1
- 108700028146 Genetic Enhancer Elements Proteins 0.000 description 1
- 239000004471 Glycine Substances 0.000 description 1
- NYHBQMYGNKIUIF-UUOKFMHZSA-N Guanosine Chemical compound C1=NC=2C(=O)NC(N)=NC=2N1[C@@H]1O[C@H](CO)[C@@H](O)[C@H]1O NYHBQMYGNKIUIF-UUOKFMHZSA-N 0.000 description 1
- 108010001336 Horseradish Peroxidase Proteins 0.000 description 1
- 102000001706 Immunoglobulin Fab Fragments Human genes 0.000 description 1
- 108010054477 Immunoglobulin Fab Fragments Proteins 0.000 description 1
- KFZMGEQAYNKOFK-UHFFFAOYSA-N Isopropanol Chemical compound CC(C)O KFZMGEQAYNKOFK-UHFFFAOYSA-N 0.000 description 1
- QIVBCDIJIAJPQS-VIFPVBQESA-N L-tryptophane Chemical compound C1=CC=C2C(C[C@H](N)C(O)=O)=CNC2=C1 QIVBCDIJIAJPQS-VIFPVBQESA-N 0.000 description 1
- 102000003960 Ligases Human genes 0.000 description 1
- 108090000364 Ligases Proteins 0.000 description 1
- 241000124008 Mammalia Species 0.000 description 1
- 125000000729 N-terminal amino-acid group Chemical group 0.000 description 1
- 229930193140 Neomycin Natural products 0.000 description 1
- 108091093105 Nuclear DNA Proteins 0.000 description 1
- 108020004711 Nucleic Acid Probes Proteins 0.000 description 1
- 108010038807 Oligopeptides Proteins 0.000 description 1
- 102000015636 Oligopeptides Human genes 0.000 description 1
- 102000004160 Phosphoric Monoester Hydrolases Human genes 0.000 description 1
- 108090000608 Phosphoric Monoester Hydrolases Proteins 0.000 description 1
- OAICVXFJPJFONN-UHFFFAOYSA-N Phosphorus Chemical compound [P] OAICVXFJPJFONN-UHFFFAOYSA-N 0.000 description 1
- 229920003171 Poly (ethylene oxide) Polymers 0.000 description 1
- 108010076504 Protein Sorting Signals Proteins 0.000 description 1
- 102000002067 Protein Subunits Human genes 0.000 description 1
- 108010001267 Protein Subunits Proteins 0.000 description 1
- BFDMCHRDSYTOLE-UHFFFAOYSA-N SC#N.NC(N)=N.ClC(Cl)Cl.OC1=CC=CC=C1 Chemical compound SC#N.NC(N)=N.ClC(Cl)Cl.OC1=CC=CC=C1 BFDMCHRDSYTOLE-UHFFFAOYSA-N 0.000 description 1
- 241000293869 Salmonella enterica subsp. enterica serovar Typhimurium Species 0.000 description 1
- 229920005654 Sephadex Polymers 0.000 description 1
- 239000012507 Sephadex™ Substances 0.000 description 1
- 238000012300 Sequence Analysis Methods 0.000 description 1
- VMHLLURERBWHNL-UHFFFAOYSA-M Sodium acetate Chemical compound [Na+].CC([O-])=O VMHLLURERBWHNL-UHFFFAOYSA-M 0.000 description 1
- 241000187747 Streptomyces Species 0.000 description 1
- 229930006000 Sucrose Natural products 0.000 description 1
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 1
- QAOWNCQODCNURD-UHFFFAOYSA-N Sulfuric acid Chemical compound OS(O)(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-N 0.000 description 1
- 102000004385 Sulfurtransferases Human genes 0.000 description 1
- 108090000984 Sulfurtransferases Proteins 0.000 description 1
- 108700007696 Tetrahydrofolate Dehydrogenase Proteins 0.000 description 1
- 102000006601 Thymidine Kinase Human genes 0.000 description 1
- 108020004440 Thymidine kinase Proteins 0.000 description 1
- 108700029229 Transcriptional Regulatory Elements Proteins 0.000 description 1
- QIVBCDIJIAJPQS-UHFFFAOYSA-N Tryptophan Natural products C1=CC=C2C(CC(N)C(O)=O)=CNC2=C1 QIVBCDIJIAJPQS-UHFFFAOYSA-N 0.000 description 1
- 239000006035 Tryptophane Substances 0.000 description 1
- 244000301083 Ustilago maydis Species 0.000 description 1
- 235000009754 Vitis X bourquina Nutrition 0.000 description 1
- 235000012333 Vitis X labruscana Nutrition 0.000 description 1
- 240000006365 Vitis vinifera Species 0.000 description 1
- 235000014787 Vitis vinifera Nutrition 0.000 description 1
- 230000002378 acidificating effect Effects 0.000 description 1
- 230000009471 action Effects 0.000 description 1
- 125000002252 acyl group Chemical group 0.000 description 1
- 238000005377 adsorption chromatography Methods 0.000 description 1
- 238000001042 affinity chromatography Methods 0.000 description 1
- 239000003513 alkali Substances 0.000 description 1
- 125000000217 alkyl group Chemical group 0.000 description 1
- 239000005030 aluminium foil Substances 0.000 description 1
- 238000003277 amino acid sequence analysis Methods 0.000 description 1
- 239000012491 analyte Substances 0.000 description 1
- 230000002788 anti-peptide Effects 0.000 description 1
- 239000003816 antisense DNA Substances 0.000 description 1
- 238000013459 approach Methods 0.000 description 1
- 239000008346 aqueous phase Substances 0.000 description 1
- 238000003149 assay kit Methods 0.000 description 1
- 230000037444 atrophy Effects 0.000 description 1
- 238000002869 basic local alignment search tool Methods 0.000 description 1
- 230000008901 benefit Effects 0.000 description 1
- 150000004054 benzoquinones Chemical class 0.000 description 1
- 210000003445 biliary tract Anatomy 0.000 description 1
- 230000000975 bioactive effect Effects 0.000 description 1
- 238000011953 bioanalysis Methods 0.000 description 1
- 230000033228 biological regulation Effects 0.000 description 1
- 230000000903 blocking effect Effects 0.000 description 1
- 210000004204 blood vessel Anatomy 0.000 description 1
- 238000009835 boiling Methods 0.000 description 1
- 102220369447 c.1352G>A Human genes 0.000 description 1
- 102220369445 c.668T>C Human genes 0.000 description 1
- 239000001506 calcium phosphate Substances 0.000 description 1
- 229910000389 calcium phosphate Inorganic materials 0.000 description 1
- 235000011010 calcium phosphates Nutrition 0.000 description 1
- GYSSRZJIHXQEHQ-UHFFFAOYSA-N carboxin Chemical class S1CCOC(C)=C1C(=O)NC1=CC=CC=C1 GYSSRZJIHXQEHQ-UHFFFAOYSA-N 0.000 description 1
- 239000000969 carrier Substances 0.000 description 1
- 230000003197 catalytic effect Effects 0.000 description 1
- 230000004663 cell proliferation Effects 0.000 description 1
- 239000001913 cellulose Substances 0.000 description 1
- 229920002678 cellulose Polymers 0.000 description 1
- 201000001883 cholelithiasis Diseases 0.000 description 1
- 239000012916 chromogenic reagent Substances 0.000 description 1
- 230000004087 circulation Effects 0.000 description 1
- 208000019425 cirrhosis of liver Diseases 0.000 description 1
- 238000000975 co-precipitation Methods 0.000 description 1
- 239000011248 coating agent Substances 0.000 description 1
- 238000000576 coating method Methods 0.000 description 1
- ACTIUHUUMQJHFO-UPTCCGCDSA-N coenzyme Q10 Chemical compound COC1=C(OC)C(=O)C(C\C=C(/C)CC\C=C(/C)CC\C=C(/C)CC\C=C(/C)CC\C=C(/C)CC\C=C(/C)CC\C=C(/C)CC\C=C(/C)CC\C=C(/C)CCC=C(C)C)=C(C)C1=O ACTIUHUUMQJHFO-UPTCCGCDSA-N 0.000 description 1
- 235000017471 coenzyme Q10 Nutrition 0.000 description 1
- 239000000084 colloidal system Substances 0.000 description 1
- 210000003459 common hepatic duct Anatomy 0.000 description 1
- 239000003184 complementary RNA Substances 0.000 description 1
- 239000012141 concentrate Substances 0.000 description 1
- 230000001143 conditioned effect Effects 0.000 description 1
- 238000010276 construction Methods 0.000 description 1
- 230000001186 cumulative effect Effects 0.000 description 1
- 238000005520 cutting process Methods 0.000 description 1
- ATDGTVJJHBUTRL-UHFFFAOYSA-N cyanogen bromide Chemical compound BrC#N ATDGTVJJHBUTRL-UHFFFAOYSA-N 0.000 description 1
- SUYVUBYJARFZHO-RRKCRQDMSA-N dATP Chemical compound C1=NC=2C(N)=NC=NC=2N1[C@H]1C[C@H](O)[C@@H](COP(O)(=O)OP(O)(=O)OP(O)(O)=O)O1 SUYVUBYJARFZHO-RRKCRQDMSA-N 0.000 description 1
- SUYVUBYJARFZHO-UHFFFAOYSA-N dATP Natural products C1=NC=2C(N)=NC=NC=2N1C1CC(O)C(COP(O)(=O)OP(O)(=O)OP(O)(O)=O)O1 SUYVUBYJARFZHO-UHFFFAOYSA-N 0.000 description 1
- 230000006378 damage Effects 0.000 description 1
- 230000034994 death Effects 0.000 description 1
- 238000012217 deletion Methods 0.000 description 1
- 230000037430 deletion Effects 0.000 description 1
- 238000011161 development Methods 0.000 description 1
- 102000004419 dihydrofolate reductase Human genes 0.000 description 1
- 239000003085 diluting agent Substances 0.000 description 1
- 229940079593 drug Drugs 0.000 description 1
- 235000013399 edible fruits Nutrition 0.000 description 1
- 238000006911 enzymatic reaction Methods 0.000 description 1
- 210000000981 epithelium Anatomy 0.000 description 1
- 238000011156 evaluation Methods 0.000 description 1
- 238000010195 expression analysis Methods 0.000 description 1
- 238000000605 extraction Methods 0.000 description 1
- GNBHRKFJIUUOQI-UHFFFAOYSA-N fluorescein Chemical compound O1C(=O)C2=CC=CC=C2C21C1=CC=C(O)C=C1OC1=CC(O)=CC=C21 GNBHRKFJIUUOQI-UHFFFAOYSA-N 0.000 description 1
- 238000009472 formulation Methods 0.000 description 1
- 238000006062 fragmentation reaction Methods 0.000 description 1
- 230000002538 fungal effect Effects 0.000 description 1
- 238000002523 gelfiltration Methods 0.000 description 1
- 230000030279 gene silencing Effects 0.000 description 1
- 238000012226 gene silencing method Methods 0.000 description 1
- 238000001415 gene therapy Methods 0.000 description 1
- 239000003292 glue Substances 0.000 description 1
- RWSXRVCMGQZWBV-WDSKDSINSA-N glutathione Chemical compound OC(=O)[C@@H](N)CCC(=O)N[C@@H](CS)C(=O)NCC(O)=O RWSXRVCMGQZWBV-WDSKDSINSA-N 0.000 description 1
- 239000010931 gold Substances 0.000 description 1
- 229910052737 gold Inorganic materials 0.000 description 1
- 230000012010 growth Effects 0.000 description 1
- ZRALSGWEFCBTJO-UHFFFAOYSA-O guanidinium Chemical compound NC(N)=[NH2+] ZRALSGWEFCBTJO-UHFFFAOYSA-O 0.000 description 1
- ZJYYHGLJYGJLLN-UHFFFAOYSA-N guanidinium thiocyanate Chemical compound SC#N.NC(N)=N ZJYYHGLJYGJLLN-UHFFFAOYSA-N 0.000 description 1
- 230000036541 health Effects 0.000 description 1
- 230000002440 hepatic effect Effects 0.000 description 1
- 238000004128 high performance liquid chromatography Methods 0.000 description 1
- HNDVDQJCIGZPNO-UHFFFAOYSA-N histidine Natural products OC(=O)C(N)CC1=CN=CN1 HNDVDQJCIGZPNO-UHFFFAOYSA-N 0.000 description 1
- 150000002411 histidines Chemical class 0.000 description 1
- 210000004408 hybridoma Anatomy 0.000 description 1
- 230000007062 hydrolysis Effects 0.000 description 1
- 238000006460 hydrolysis reaction Methods 0.000 description 1
- WGCNASOHLSPBMP-UHFFFAOYSA-N hydroxyacetaldehyde Natural products OCC=O WGCNASOHLSPBMP-UHFFFAOYSA-N 0.000 description 1
- 206010020718 hyperplasia Diseases 0.000 description 1
- 230000028993 immune response Effects 0.000 description 1
- 238000003317 immunochromatography Methods 0.000 description 1
- 238000003364 immunohistochemistry Methods 0.000 description 1
- 238000001114 immunoprecipitation Methods 0.000 description 1
- 238000000338 in vitro Methods 0.000 description 1
- 238000001727 in vivo Methods 0.000 description 1
- 238000011534 incubation Methods 0.000 description 1
- 230000006698 induction Effects 0.000 description 1
- 230000001939 inductive effect Effects 0.000 description 1
- 230000008595 infiltration Effects 0.000 description 1
- 238000001764 infiltration Methods 0.000 description 1
- 238000002347 injection Methods 0.000 description 1
- 239000007924 injection Substances 0.000 description 1
- 238000007689 inspection Methods 0.000 description 1
- 238000009413 insulation Methods 0.000 description 1
- 238000004255 ion exchange chromatography Methods 0.000 description 1
- 238000002955 isolation Methods 0.000 description 1
- 229960000310 isoleucine Drugs 0.000 description 1
- AGPKZVBTJJNPAG-UHFFFAOYSA-N isoleucine Natural products CCC(C)C(N)C(O)=O AGPKZVBTJJNPAG-UHFFFAOYSA-N 0.000 description 1
- BPHPUYQFMNQIOC-NXRLNHOXSA-N isopropyl beta-D-thiogalactopyranoside Chemical compound CC(C)S[C@@H]1O[C@H](CO)[C@H](O)[C@H](O)[C@H]1O BPHPUYQFMNQIOC-NXRLNHOXSA-N 0.000 description 1
- 230000000155 isotopic effect Effects 0.000 description 1
- 230000002147 killing effect Effects 0.000 description 1
- 208000019423 liver disease Diseases 0.000 description 1
- 230000005976 liver dysfunction Effects 0.000 description 1
- 230000004807 localization Effects 0.000 description 1
- 230000033001 locomotion Effects 0.000 description 1
- 238000010841 mRNA extraction Methods 0.000 description 1
- 238000004949 mass spectrometry Methods 0.000 description 1
- 238000010297 mechanical methods and process Methods 0.000 description 1
- 230000010534 mechanism of action Effects 0.000 description 1
- 201000001441 melanoma Diseases 0.000 description 1
- 210000004379 membrane Anatomy 0.000 description 1
- 208000030159 metabolic disease Diseases 0.000 description 1
- 230000002503 metabolic effect Effects 0.000 description 1
- 230000031864 metaphase Effects 0.000 description 1
- WSFSSNUMVMOOMR-NJFSPNSNSA-N methanone Chemical compound O=[14CH2] WSFSSNUMVMOOMR-NJFSPNSNSA-N 0.000 description 1
- 238000000520 microinjection Methods 0.000 description 1
- 210000003470 mitochondria Anatomy 0.000 description 1
- 210000001700 mitochondrial membrane Anatomy 0.000 description 1
- 230000009456 molecular mechanism Effects 0.000 description 1
- 230000000877 morphologic effect Effects 0.000 description 1
- 239000005445 natural material Substances 0.000 description 1
- 229960004927 neomycin Drugs 0.000 description 1
- 239000002853 nucleic acid probe Substances 0.000 description 1
- 235000015097 nutrients Nutrition 0.000 description 1
- 210000004681 ovum Anatomy 0.000 description 1
- 230000003647 oxidation Effects 0.000 description 1
- 238000007254 oxidation reaction Methods 0.000 description 1
- 239000002245 particle Substances 0.000 description 1
- 244000052769 pathogen Species 0.000 description 1
- 230000001717 pathogenic effect Effects 0.000 description 1
- 230000036285 pathological change Effects 0.000 description 1
- 231100000915 pathological change Toxicity 0.000 description 1
- 239000008194 pharmaceutical composition Substances 0.000 description 1
- 239000000546 pharmaceutical excipient Substances 0.000 description 1
- 239000012071 phase Substances 0.000 description 1
- 238000002264 polyacrylamide gel electrophoresis Methods 0.000 description 1
- 229920002981 polyvinylidene fluoride Polymers 0.000 description 1
- 239000013641 positive control Substances 0.000 description 1
- 229910000027 potassium carbonate Inorganic materials 0.000 description 1
- 238000004321 preservation Methods 0.000 description 1
- 230000002265 prevention Effects 0.000 description 1
- 230000003449 preventive effect Effects 0.000 description 1
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 description 1
- 230000037452 priming Effects 0.000 description 1
- 230000035755 proliferation Effects 0.000 description 1
- 230000022558 protein metabolic process Effects 0.000 description 1
- 238000001742 protein purification Methods 0.000 description 1
- 238000003156 radioimmunoprecipitation Methods 0.000 description 1
- NPCOQXAVBJJZBQ-UHFFFAOYSA-N reduced coenzyme Q9 Natural products COC1=C(O)C(C)=C(CC=C(C)CCC=C(C)CCC=C(C)CCC=C(C)CCC=C(C)CCC=C(C)CCC=C(C)CCC=C(C)CCC=C(C)C)C(O)=C1OC NPCOQXAVBJJZBQ-UHFFFAOYSA-N 0.000 description 1
- 230000009467 reduction Effects 0.000 description 1
- 230000002829 reductive effect Effects 0.000 description 1
- 238000004153 renaturation Methods 0.000 description 1
- 239000002342 ribonucleoside Substances 0.000 description 1
- 230000000630 rising effect Effects 0.000 description 1
- 102220023257 rs387907546 Human genes 0.000 description 1
- 102220023256 rs387907547 Human genes 0.000 description 1
- 210000003296 saliva Anatomy 0.000 description 1
- 235000019515 salmon Nutrition 0.000 description 1
- 238000004062 sedimentation Methods 0.000 description 1
- 230000035945 sensitivity Effects 0.000 description 1
- 238000012163 sequencing technique Methods 0.000 description 1
- 235000020183 skimmed milk Nutrition 0.000 description 1
- 239000001632 sodium acetate Substances 0.000 description 1
- 235000017281 sodium acetate Nutrition 0.000 description 1
- 239000001509 sodium citrate Substances 0.000 description 1
- 210000001082 somatic cell Anatomy 0.000 description 1
- 238000010183 spectrum analysis Methods 0.000 description 1
- 238000010561 standard procedure Methods 0.000 description 1
- 238000003756 stirring Methods 0.000 description 1
- 108010011792 succinate oxidase Proteins 0.000 description 1
- 239000005720 sucrose Substances 0.000 description 1
- 239000001117 sulphuric acid Substances 0.000 description 1
- 235000011149 sulphuric acid Nutrition 0.000 description 1
- 239000006228 supernatant Substances 0.000 description 1
- 239000000725 suspension Substances 0.000 description 1
- 238000003786 synthesis reaction Methods 0.000 description 1
- 238000010257 thawing Methods 0.000 description 1
- 230000001225 therapeutic effect Effects 0.000 description 1
- 210000001541 thymus gland Anatomy 0.000 description 1
- 238000003151 transfection method Methods 0.000 description 1
- 230000001131 transforming effect Effects 0.000 description 1
- 230000007704 transition Effects 0.000 description 1
- 238000013519 translation Methods 0.000 description 1
- 230000014621 translational initiation Effects 0.000 description 1
- 230000032258 transport Effects 0.000 description 1
- QORWJWZARLRLPR-UHFFFAOYSA-H tricalcium bis(phosphate) Chemical compound [Ca+2].[Ca+2].[Ca+2].[O-]P([O-])([O-])=O.[O-]P([O-])([O-])=O QORWJWZARLRLPR-UHFFFAOYSA-H 0.000 description 1
- HRXKRNGNAMMEHJ-UHFFFAOYSA-K trisodium citrate Chemical compound [Na+].[Na+].[Na+].[O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O HRXKRNGNAMMEHJ-UHFFFAOYSA-K 0.000 description 1
- 229940038773 trisodium citrate Drugs 0.000 description 1
- 229960004799 tryptophan Drugs 0.000 description 1
- 229940035936 ubiquinone Drugs 0.000 description 1
- 238000002525 ultrasonication Methods 0.000 description 1
- 241000701447 unidentified baculovirus Species 0.000 description 1
- 210000002700 urine Anatomy 0.000 description 1
- 229940125575 vaccine candidate Drugs 0.000 description 1
- 238000001291 vacuum drying Methods 0.000 description 1
- 238000011179 visual inspection Methods 0.000 description 1
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 1
- 238000001262 western blot Methods 0.000 description 1
- 206010048282 zoonosis Diseases 0.000 description 1
Landscapes
- Enzymes And Modification Thereof (AREA)
- Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
Abstract
The invention discloses new genes for encoding clonorchiasis sinensis succinate dehydrogenase Ip subunit, polypeptides encoded by the genes, and antibody of the polypeptides. The invention also discloses the depressor of the polypeptides for screening clonorchiaswis sinensis succinate dehydrogenase Ip subunit, the use of polynucleotides as primer or as probe, in particular the use of the polypeptide and polynucleotide as diagnosis reagent kit, and vaccine.
Description
Technical field
The invention belongs to biological technical field, specifically, the invention describes a kind of new polypeptide---liver fluke succinodehydrogenase Ip subunit, and the polynucleotide sequence of this polypeptide of encoding.The invention still further relates to the application of these polynucleotide and polypeptide.
Background technology
Liver fluke (a China testis adult) is a zoonosis, adult colonizes in the hepatic duct, and adult can be destroyed blood vessel under biliary tract epithelium and the mucous membrane, and produces secretion drainage antigen, cause the inflammatory reaction on every side of bile duct and bile duct, cause expansion of bile duct limitation and bile duct epithelial cell hyperplasia.Some antigenic components can also enter hepatic tissue by bile duct epithelial cell, and reaction and liver dysfunction cause inflammation.Secular severe infections can cause proliferation of fibrous tissue and hepatocellular atrophy sex change, even causes canceration, ascites and liver cirrhosis.Liver fluke occupies bile duct, and it is not smooth to make that bile flows out, and easily merges infectation of bacteria and cholelithiasis occurs.
The control of rot mainly relies on comprehensive preventive health measures.At the mass screening and mass treatment of popular district reinforcement to the crowd, and the development of reinforcement vaccine, to reduce contagium and protection Susceptible population.At present, the emphasis of rot study on prevention concentrates on diagnosis and vaccine candidate antigen, drug targets, morbific molecular mechanism research.
In the organism, sugar not only plays the effect that makes up tissue, and the important molecule of energy is provided for body especially.In the aerobic oxidation of glycolysis-or sugar, succinodehydrogenase/fumaric reductase plays an important role.
Biological intravital composite I I has two kinds, in aerobic environment, is induced by the succinodehydrogenase of sdh operon coding; In oxygen-free environment, induced by the fumaric reductase of frd operon coding.In aerobic environment, derivative composite I I shows as succinic dehydrogenase activity, and the catalysis succinoxidase changes into fumaric acid and discharges 2 electronics, again it is passed to benzoquinones and is converted into Resorcinol; Oxygen-free environment inductive mixture shows as the oxidasic activity of fumaric acid, the reaction [Cecilia Hagerhall.1997, Biochimica et BiophysicaActa, 1320:107-141] that catalysis is opposite with the catalytic reaction of succinodehydrogenase.
Though succinodehydrogenase is different with the catalytic reaction of fumaric reductase, both structural similitudies.Composite I I is positioned at cytolemma at prokaryotic cell prokaryocyte, is positioned at mitochondrial membrane at eukaryotic cell, by the nuclear dna encoding.It is made up of four subunits, wherein two subunits are formed the part of succinodehydrogenases (SDH), and big subunit is the flavoprotein (Fp) of 70Kda, and little subunit is iron-sulfoprotein (an Ip subunit), molecular weight has 30Kda, the Ip subunit contains 3 different iron-methylthio groups, [2Fe-2S] 2+, 1+, [4Fe-4S] 2+, 1+, [3Fe-4S] 1+, 0.The SDH that Fp and Ip form is anchored on [Harry C.Au, et al., 1995, Gene, 159:249-253] on the film by two other subunit C and D (15 and 12.5Kda).SDH is an enzyme important in the carbohydrate metabolism, can design as desinsection or germ killing drugs at antagonist or the inhibitor of SDH.As carboxanilides is the strong inhibitor of fungi, bacterium and animal mitochondria, and carboxin class inhibitor effect mainly be the electron transport that interrupts between center of Ip subunit 3 and the ubiquinone.As in the mutation of the anti-carboxin of u.maydis, difference between itself and non-resistance kind is that the center 3 of only Ip subunit has an amino acid that variation has taken place, promptly 257 Histidine has been transformed into leucine [Toshikazu Irie, et al., 1998, Biochimica et Biophysica Acta, 1396:27-31].Therefore, the structure of research Ip subunit and function have important use to be worth.
Thunberg recorded the SDH activity for the first time from frog in 1909.Darlison1984 has found and has measured the gene order of four subunits of coding E.coli succinodehydrogenase.Behind the Ip subunit cDNA of Lombardo1990 clone Saccharomycescerenisiae, the determined and clone of the Ip subunit in a lot of things.
Because the succinodehydrogenase of Ip subunit participation plays an important role in the function carbohydrate metabolism of body as mentioned above, and believe and relate to a large amount of albumen in these regulate processes, thereby need to identify the albumen of more these processes of participation in this area always, particularly identify this proteic aminoacid sequence.The separation of new succinodehydrogenase Ip subunit coding gene also provides the foundation for determining the effect of this albumen in the liver fluke carbohydrate metabolism.This albumen may constitute the basis of exploitation curative, and it is very important therefore separating its coding DNA.
The inventor has separated code liver fluke succinate dehydrogenase subunit DNA through extensive and deep research from the liver fluke kind, and expression and purification liver fluke succinodehydrogenase Ip subunit, and further disclosed application based on these polynucleotide and polypeptide.
Summary of the invention
An object of the present invention is to provide isolating new polypeptide---liver fluke succinodehydrogenase Ip subunit with and fragment, analogue and derivative.
Another object of the present invention provides the polynucleotide of this polypeptide of coding.
Another object of the present invention provides at polypeptide of the present invention---the antibody of liver fluke succinodehydrogenase Ip subunit.
Another object of the present invention has provided the polynucleotide that suppress expression of polypeptides of the present invention.
Another object of the present invention provides the inhibitor that polypeptide of the present invention is applied to screen liver fluke succinodehydrogenase Ip subunit; Perhaps be used for the peptide finger print identification.
Another object of the present invention provides nucleic acid molecule of the present invention and is used for nucleic acid amplification reaction as primer, perhaps is used for hybridization as probe, perhaps is used to make the application of gene chip or microarray.
Another object of the present invention provides a kind of test kit that detects liver fluke, and it contains primer, antibody or the polypeptide of specific detection liver fluke succinodehydrogenase Ip subunit itself.
Another object of the present invention provides a kind of vaccine that is used to prevent rot, and it contains the carrier for expression of eukaryon of the polynucleotide of liver fluke succinodehydrogenase Ip subunit or this polypeptide of encoding.
In a first aspect of the present invention, the present invention relates to a kind of isolated polypeptide, this polypeptide is the liver fluke source, it comprises: polypeptide or its examples of conservative variations, bioactive fragment or derivative with SEQ ID No.2 aminoacid sequence.Preferably, this polypeptide is the polypeptide with SEQ ID NO:2 aminoacid sequence.More preferably, this polypeptide does not contain signal peptide sequence.
In a second aspect of the present invention, the invention still further relates to a kind of isolating polynucleotide, it comprises a kind of nucleotide sequence or its variant that is selected from down group:
(a) coding has the polynucleotide of the polypeptide of SEQ ID No.2 aminoacid sequence;
(b) with polynucleotide (a) complementary polynucleotide;
More preferably, the sequence of these polynucleotide is be selected from down group a kind of: the sequence that (a) has 47-880 position among the SEQ ID NO:1; (b) has the sequence of 1-1011 position among the SEQ ID NO:1.
In a third aspect of the present invention, the invention still further relates to a kind of can with polypeptid specificity bonded antibody of the present invention.
In a fourth aspect of the present invention, the polynucleotide that suppress expression of polypeptides of the present invention are provided.
In a fifth aspect of the present invention, provide the purposes of polypeptide of the present invention and encoding sequence.For example, utilize polypeptide to be applied to screen the inhibitor of liver fluke succinodehydrogenase Ip subunit, the inhibitor that is filtered out is formed the pharmaceutical composition of treatment rot with safe and effective dosage and pharmaceutically acceptable excipient; Perhaps be used for the peptide finger print identification.Utilize encoding sequence or its fragment to be used for nucleic acid amplification reaction, perhaps be used for hybridization, perhaps be used to make the application of gene chip or microarray as probe as primer.
In a sixth aspect of the present invention, a kind of test kit that detects liver fluke is provided, it contains primer, antibody or the polypeptide of specific detection liver fluke succinodehydrogenase Ip subunit itself.
In a seventh aspect of the present invention, a kind of vaccine that is used to prevent liver fluke is provided, it contains the carrier for expression of eukaryon of the polynucleotide of liver fluke succinodehydrogenase Ip subunit or this polypeptide of encoding.
Others of the present invention for example, utilize the present invention can relate to a kind of carrier that contains polynucleotide of the present invention, particularly expression vector because disclosing of the technology of this paper is conspicuous to those skilled in the art; The host cell that this carrier of a kind of usefulness is genetically engineered comprises the host cell of conversion, transduction or transfection; A kind of method for preparing polypeptide of the present invention of cultivating described host cell and reclaiming expression product that comprises.
The following term of using in this specification sheets and claims has following implication unless stated otherwise:
" nucleotide sequence " is meant oligonucleotide, Nucleotide or polynucleotide and fragment or part, also can refer to genome or synthetic DNA or RNA, and they can be strand or two strands, represent sense strand or antisense strand.Similarly, term " aminoacid sequence " is meant oligopeptides, peptide, polypeptide or protein sequence and fragment or part.When " aminoacid sequence " among the present invention related to a kind of aminoacid sequence of naturally occurring protein molecule, this " polypeptide " or " protein " did not mean that aminoacid sequence are restricted to the complete natural amino acid relevant with described protein molecule.
Protein or polynucleotide " variant " are meant a kind of polynucleotide sequence that has the aminoacid sequence of one or more amino acid or Nucleotide change or encode it.Described change can comprise disappearance, insertion or the replacement of amino acid in aminoacid sequence or the nucleotide sequence or Nucleotide.Variant can have " conservative property " and change, and wherein the amino acid of Ti Huaning has structure or the chemical property similar with original acid, as replacing Isoleucine with leucine.Variant also can have non-conservation and change, as replacing glycine with tryptophane.
" biological activity " is meant the protein of structure, regulation and control or biochemical function with natural molecule.Similarly, term " immunologic competence " be meant natural, reorganization or synthetic protein and fragment thereof in suitable animal or cell, induce specific immune response and with specific antibody bonded ability.
" inhibition " is meant when combining with liver fluke succinodehydrogenase Ip subunit, a kind of molecule that seals or regulate the biologic activity of liver fluke succinodehydrogenase Ip subunit.Inhibition can comprise protein, nucleic acid, carbohydrate or any other can be in conjunction with the molecule of liver fluke succinodehydrogenase Ip subunit.
" adjusting " is meant that the function of liver fluke succinodehydrogenase Ip subunit changes, and comprises the change of any other biological property, function or the immune property of the change of the rising of protein active or reduction, binding characteristic and liver fluke succinodehydrogenase Ip subunit.
" pure basically " is meant and is substantially free of natural relative other albumen, lipid, carbohydrate or other material.Those skilled in the art can use the purified technology of protein purifying liver fluke succinodehydrogenase Ip subunit of standard.Basically pure liver fluke succinodehydrogenase Ip subunit can produce single master tape on the irreducibility polyacrylamide gel.The purity available amino end acid sequence of liver fluke succinodehydrogenase Ip subunit polypeptide is analyzed.
" complementary " or " complementation " is meant under salt concn that allows and temperature condition by the natural combination of the polynucleotide of base pairing.For example, sequence " C-T-G-A " can combine with complementary sequence " G-A-C-T ".Complementation between two single chain molecules can be part or whole.Complementary degree between the nucleic acid chains has a significant effect for efficient of hybridizing between the nucleic acid chains and intensity.
" homology " is meant the complementary degree, can be portion homologous or complete homology." portion homologous " is meant a kind of part complementary sequence, and it can partly suppress the hybridization of complete complementary sequence and target nucleic acid at least.The inhibition of this hybridization can detect by hybridizing (Southern trace or Northern trace etc.) under the condition that reduces in the severity degree.Basically homologous sequence or hybridization probe can compete and suppress complete homologous sequence and target sequence the condition that reduces of severity degree under combine.This does not mean the conditions permit non-specific binding that the severity degree reduces because the conditional request two sequences that the severity degree reduces mutual be combined into specificity or selectivity interacts.
" antisense " is meant and specific DNA or RNA sequence complementary nucleotide sequence." antisense strand " is meant and " sense strand " complementary nucleic acid chains.
" derivative " is meant HFP or encodes its chemical modification object of nucleic acid.This chemical modification object can be with alkyl, acyl group or the amino hydrogen atom of replacing.The nucleic acid derivative codified keeps the polypeptide of the main biological characteristics of natural molecule.
" antibody " is meant complete antibody molecule and fragment thereof, as Fab, F (ab ')
2And Fv, its energy specificity is in conjunction with the antigenic determinant of liver fluke succinodehydrogenase Ip subunit.
" isolating " speech refers to material is shifted out among its original environment (for example, if spontaneous its natural surroundings that just refers to).Such as it is exactly not to be separated that spontaneous polynucleotide or polypeptide are present in the Live Animals, but same polynucleotide or polypeptide with some or all in natural system with it the material of coexistence separately be exactly isolating.Such polynucleotide may be the parts of a certain carrier, the part that also possible such polynucleotide or polypeptide are a certain composition.Since carrier or composition are not the compositions of its natural surroundings, they remain isolating.
As used herein, " isolating " are meant that material separates (if natural substance, primal environment promptly is a natural surroundings) from its primal environment.Do not have separation and purification as polynucleotide under the native state in the active somatic cell and polypeptide, but same polynucleotide or polypeptide as from native state with in other materials that exist separately, then for separation and purification.
As used herein, " isolating liver fluke succinodehydrogenase Ip subunit " is meant that liver fluke succinodehydrogenase Ip subunit is substantially free of natural relative other albumen, lipid, carbohydrate or other material.Those skilled in the art can use the purified technology of protein purifying liver fluke succinodehydrogenase Ip subunit of standard.Basically pure polypeptide can produce single master tape on non-reduced polyacrylamide gel.The purity of liver fluke succinodehydrogenase Ip subunit polypeptide can be used amino acid sequence analysis.
In a first aspect of the present invention, the invention provides a kind of new polypeptide---liver fluke succinodehydrogenase Ip subunit, it is made up of the aminoacid sequence shown in the SEQ ID NO:2 basically.Polypeptide of the present invention can be recombinant polypeptide, natural polypeptides, synthetic polypeptide, preferred recombinant polypeptide.Polypeptide of the present invention can be the product of natural purifying, or the product of chemosynthesis, or uses recombinant technology to produce from protokaryon or eucaryon host (for example, bacterium, yeast, higher plant, insect and mammalian cell).The host used according to the recombinant production scheme, polypeptide of the present invention can be glycosylated, maybe can be nonglycosylated.Polypeptide of the present invention also can comprise or not comprise initial methionine residues.
The present invention also comprises fragment, derivative and the analogue of liver fluke succinodehydrogenase Ip subunit.As used herein, term " fragment ", " derivative " are meant with " analogue " and keep identical biological function or the active polypeptide of liver fluke succinodehydrogenase Ip subunit of the present invention basically.The fragment of polypeptide of the present invention, derivative or analogue can be: (I) a kind of like this, wherein one or more amino-acid residues are replaced by conservative or non-conservative amino acid residues (preferably conservative amino acid residues), and the amino acid that replaces can be also can not encoded by genetic codon; Perhaps (II) is a kind of like this, and certain group on wherein one or more amino-acid residues is replaced by other group and comprises substituting group; Perhaps (III) is a kind of like this, and wherein mature polypeptide and another kind of compound (such as the compound that prolongs the polypeptide transformation period, for example polyoxyethylene glycol) merge; Perhaps (IV) is a kind of like this, wherein additional aminoacid sequence is integrated into mature polypeptide and the peptide sequence that forms (as leader sequence or secretion sequence or be used for the sequence or the proteinogen sequence of this polypeptide of purifying) by the elaboration of this paper, such fragment, derivative and analogue are considered within those skilled in the art's ken.
In a second aspect of the present invention, the invention provides isolating polynucleotide, substantially the polynucleotide that have a polypeptide of SEQ ID NO:2 aminoacid sequence by coding are formed.Polynucleotide sequence of the present invention comprises the nucleotide sequence of SEQ ID NO:1.Polynucleotide of the present invention are to prop up testis from China to be tied to form the full-length cDNA library of worm and to find.The polynucleotide sequence total length that it comprises is 1011 bases, its open reading frame (47-880) 278 amino acid of having encoded.Find relatively that according to amino acid sequence homologous this polypeptide and people's succinodehydrogenase Ip subunit have 83% homology, it is exactly liver fluke succinodehydrogenase Ip subunit that deducibility goes out this albumen.
Polynucleotide of the present invention can be dna form or rna form.Dna form comprises the DNA of cDNA, genomic dna or synthetic.DNA can be strand or double-stranded.DNA can be coding strand or noncoding strand.The coding region sequence of encoding mature polypeptide can be identical with the coding region sequence shown in the SEQ ID NO:1 or the varient of degeneracy.As used herein, " varient of degeneracy " are meant that in the present invention coding has protein or the polypeptide of SEQ ID NO:2, but with the differentiated nucleotide sequence of coding region sequence shown in the SEQ ID NO:1.
The polynucleotide of the mature polypeptide of coding SEQ ID NO:2 comprise: the encoding sequence that has only mature polypeptide; The encoding sequence of mature polypeptide and various additional code sequence; Encoding sequence of mature polypeptide (with optional additional code sequence) and non-coding sequence.
Term " polynucleotide of coded polypeptide " is meant polynucleotide that comprise this polypeptide of encoding and the polynucleotide that comprise additional code and/or non-coding sequence.
The invention still further relates to the varient of foregoing description polynucleotide, its coding has the polypeptide of identical aminoacid sequence or segment, analogue and the derivative of polypeptide with the present invention.The varient of these polynucleotide can be the allelic variant of natural generation or the varient that non-natural takes place.These nucleotide diversity bodies comprise and replace varient, deletion mutation body and insert varient.As known in the art, allelic variant is the replacement form of polynucleotide, and it may be replacement, disappearance or the insertion of one or more Nucleotide, but can be from not changing the function of its encoded polypeptides in fact.
The invention still further relates to polynucleotide with sequence hybridization described above.The present invention be more particularly directed under stringent condition and the interfertile polynucleotide of polynucleotide of the present invention.In the present invention, " stringent condition " is meant: (1) than hybridization under low ionic strength and the comparatively high temps and wash-out, as 0.2 * SSC, and 0.1%SDS, 60 ℃; Or (2) hybridization the time adds and to use denaturing agent, as 50% (v/v) methane amide, 0.1% calf serum/0.1%Ficoll, 42 ℃ etc.; Or (3) only at the homogeny between the two sequences at least more than 95%, be more preferably 97% and just hybridize when above.And the polypeptide of interfertile polynucleotide encoding has identical biological function and activity with the mature polypeptide shown in the SEQ IDNO:2.
The invention still further relates to nucleic acid fragment with sequence hybridization described above.As used herein, " nucleic acid fragment " length contain 10 Nucleotide at least, better be 20-30 Nucleotide at least, be more preferably 50-60 Nucleotide at least, preferably more than at least 100 Nucleotide.Nucleic acid fragment also can be used for the amplification technique (as PCR) of nucleic acid to determine and/or to separate the polynucleotide of code liver fluke succinate dehydrogenase subunit.
Polypeptide among the present invention and polynucleotide preferably provide with isolating form, more preferably are purified to homogeneous.
The special polynucleotide sequence of code liver fluke succinate dehydrogenase subunit of the present invention can obtain with several different methods.For example, separate polynucleotide with hybridization technique well known in the art.These technology including, but not limited to: 1) with probe and genome or the hybridization of cDNA library to detect the homologous polynucleotide sequence, 2) antibody screening of expression library is to detect the polynucleotide passage of the clone with common structure feature, 3) the isolating polynucleotide passage of expressed sequence tag (EST) technology.
Sequence dna fragment of the present invention also can obtain with following method: 1) separate double chain DNA sequence from genomic dna; 2) the chemical synthesising DNA sequence is to obtain the double-stranded DNA of described polypeptide.
In the above-mentioned method of mentioning, isolation of genomic DNA is least commonly used.The direct chemical of dna sequence dna is synthetic to be the method for often selecting for use.The more frequent method of selecting for use is the separation of cDNA sequence.The standard method that separates interested cDNA is from the donorcells separating mRNA of this gene of high expression level and carries out reverse transcription, forms plasmid or phage full-length cDNA library.Extract the existing multiple proven technique of method of mRNA, test kit also can obtain (Qiagene) from commercial channels.And the construction cDNA library also is usual method (Sambrook, et al., Molecular Cloning, A Laboratory Manual, Cold Spring Harbor Laboratory.New York, 1989).When being used in combination the polymeric enzyme reaction technology, even few expression product also can be cloned.
Available ordinary method is screened gene of the present invention from these cDNA libraries.These methods include, but is not limited to: (1) DNA-DNA or DNA-RNA hybridization; (2) appearance of marker gene function or forfeiture; (3) level of the transcript of mensuration liver fluke succinodehydrogenase Ip subunit; (4), detect the protein product of genetic expression by immunological technique or mensuration biologic activity.Aforesaid method can singly be used, but also several different methods combined utilization.
In (1) kind method, hybridizing used probe is and any a part of homology of polynucleotide of the present invention that at least 10 Nucleotide of its length better are at least 30 Nucleotide, are more preferably at least 50 Nucleotide, preferably at least 100 Nucleotide.In addition, within 2000 Nucleotide, preferable is within 1000 Nucleotide to the length of probe usually.Probe used herein is the dna sequence dna of chemosynthesis on the basis of gene order information of the present invention normally.Gene of the present invention itself or fragment are certainly as probe.The mark of dna probe can be used radio isotope, fluorescein or enzyme (as alkaline phosphatase) etc.
In (4) kind method, detect liver fluke succinodehydrogenase Ip subunit gene expressed proteins product and can use immunological technique such as Western blotting, radioimmunoprecipitation, enzyme-linked immunosorbent assay (ELISA) etc.
The method of using round pcr DNA amplification/RNA is optimized for and obtains gene of the present invention.When particularly being difficult to from the library, obtain the cDNA of total length, can preferably use RACE method (the terminal rapid amplifying method of RACE-cDNA), the primer that is used for PCR can suitably be selected according to polynucleotide sequence information of the present invention disclosed herein, and available ordinary method is synthetic.Available ordinary method is as the DNA/RNA fragment by gel electrophoresis separation and purifying amplification.
The gene of the present invention that obtains as mentioned above, perhaps the polynucleotide sequence of various dna fragmentations etc. can be used ordinary method such as double deoxidating chain termination measuring.This class polynucleotide sequence is measured also available commercial sequencing kit etc.In order to obtain the cDNA sequence of total length, order-checking need be carried out repeatedly.Sometimes need to measure a plurality of clones' cDNA sequence, just can be spliced into the cDNA sequence of total length.
The present invention also relates to comprise the carrier of polynucleotide of the present invention, and with carrier of the present invention or directly with the host cell of liver fluke succinodehydrogenase Ip subunit encoding sequence, and the method that produces polypeptide of the present invention through recombinant technology through the genetically engineered generation.
Among the present invention, the polynucleotide sequence of code liver fluke succinate dehydrogenase subunit can be inserted in the carrier, contains the recombinant vectors of polynucleotide of the present invention with formation.Term " carrier " refers to that bacterial plasmid well known in the art, phage, yeast plasmid, vegetable cell virus, mammalian cell virus are as adenovirus, retrovirus or other carrier.The carrier of Shi Yonging includes but not limited in the present invention: the expression vector based on the T7 promotor of expressing in bacterium; The pMSXND expression vector of in mammalian cell, expressing and at the carrier that derives from baculovirus of expressed in insect cells.In a word, as long as can duplicate in host and stablize, any plasmid and carrier may be used to make up recombinant expression vector.A key character of expression vector is to contain replication origin, promotor, marker gene and translational control element usually.
Method well-known to those having ordinary skill in the art can be used to make up the dna sequence dna that contains code liver fluke succinate dehydrogenase subunit and the expression vector of suitable transcribing/translational control element.These methods comprise extracorporeal recombinant DNA technology, DNA synthetic technology, the interior recombinant technology of body etc.Described dna sequence dna can effectively be connected on the suitable promotor in the expression vector, and is synthetic to instruct mRNA.The representative example of these promotors has: colibacillary lac or trp promotor; The P of lambda particles phage
LPromotor; Eukaryotic promoter comprises LTRs and some other known may command gene expression promoter in prokaryotic cell prokaryocyte or eukaryotic cell or its virus of CMV immediate early promoter, HSV thymidine kinase promoter, early stage and late period SV40 promotor, retrovirus.Expression vector also comprises ribosome bind site that translation initiation is used and transcription terminator etc.Inserting enhancer sequence in carrier will make its transcribing in higher eucaryotic cells be enhanced.Enhanser is the cis acting factor that DNA expresses, and nearly 10 to 300 base pairs act on promotor transcribing with enhancing gene usually.Can for example be included in the SV40 enhanser of 100 to 270 base pairs of replication origin side in late period one, at the polyoma enhanser of replication origin side in late period one and adenovirus enhanser etc.
In addition, expression vector preferably comprises one or more selected markers, to be provided for selecting the phenotypic character of transformed host cells, cultivate Tetrahydrofolate dehydrogenase, neomycin resistance and the green fluorescent protein (GFP) of usefulness as eukaryotic cell, or be used for colibacillary tsiklomitsin or amicillin resistance etc.
Persons skilled in the art all know how to select appropriate carriers/transcriptional regulatory element (as promotor, enhanser etc.) and selected marker.
Among the present invention, the polynucleotide of code liver fluke succinate dehydrogenase subunit or the recombinant vectors that contains these polynucleotide can transform or transduce into host cell, contain the genetically engineered host cell of these polynucleotide or recombinant vectors with formation.Term " host cell " refers to prokaryotic cell prokaryocyte, as bacterial cell; Or eukaryotic cell such as low, as yeast cell; Or higher eucaryotic cells, as mammalian cell.Representative example has: intestinal bacteria, streptomyces; Bacterial cell such as Salmonella typhimurium; Fungal cell such as yeast; Vegetable cell; Insect cell such as fruit bat S2 or Sf9; Zooblast such as CHO, COS or Bowes melanoma cells etc.
Can carry out with routine techniques well known to those skilled in the art with dna sequence dna of the present invention or the recombinant vectors transformed host cell that contains described dna sequence dna.When the host was prokaryotic organism such as intestinal bacteria, the competent cell that can absorb DNA can be used CaCl in exponential growth after date results
2Method is handled, and used step is well-known in this area.Alternative is to use MgCl
2If desired, transforming also the method for available electroporation carries out.When the host is an eukaryote, can select following DNA transfection method for use: coprecipitation of calcium phosphate method, perhaps conventional mechanical method such as microinjection, electroporation, liposome packing etc.
By the recombinant DNA technology of routine, utilize polynucleotide sequence of the present invention to can be used to express or produce the liver fluke succinodehydrogenase Ip subunit of reorganization.In general following steps are arranged:
(1). with the polynucleotide (or varient) of code liver fluke succinate dehydrogenase subunit of the present invention, or transform or the transduction proper host cell with the recombinant expression vector that contains these polynucleotide;
(2). in suitable medium, cultivate host cell;
(3). separation, protein purification from substratum or cell.
In step (2), according to used host cell, used substratum can be selected from various conventional substratum in the cultivation.Under the condition that is suitable for the host cell growth, cultivate.After host cell grows into suitable cell density, induce the promotor of selection with suitable method (as temperature transition or chemical induction), cell is cultivated for some time again.
In step (3), recombinant polypeptide can wrap and be expressed or be secreted into the extracellular in cell or on cytolemma.If desired, can utilize its physics, the separating by various separation methods with other characteristic and the albumen of purification of Recombinant of chemistry.These methods are well-known to those skilled in the art.These methods include, but are not limited to: conventional renaturation is handled, protein precipitant is handled (salt analysis method), centrifugal, the broken bacterium of infiltration, the combination of ultrasonication, super centrifugal, sieve chromatography (gel-filtration), adsorption chromatography, ion exchange chromatography, high performance liquid chromatography (HPLC) and other various liquid chromatography (LC) technology and these methods.
In a third aspect of the present invention, the invention provides and use polypeptide, and fragment, derivative as antigen to produce the method for antibody.These antibody can be polyclonal antibody or monoclonal antibody.The present invention also provides the antibody at liver fluke succinodehydrogenase Ip subunit antigen determinant.These antibody include, but is not limited to: the fragment that polyclonal antibody, monoclonal antibody, chimeric antibody, single-chain antibody, Fab fragment and Fab expression library produce.
The method of the available liver fluke succinodehydrogenase of the production of polyclonal antibody Ip subunit direct injection immune animal (as rabbit, mouse, rat etc.) obtains, and multiple adjuvant can be used for the enhancing immunity reaction, includes but not limited to freund's adjuvant etc.The technology of the monoclonal antibody of preparation liver fluke succinodehydrogenase Ip subunit includes but not limited to hybridoma technology, three knurl technology, people B-quadroma technology, EBV-hybridoma technology etc.Can be with existing technology production with the variable region bonded chimeric antibody in human constant region and inhuman source.And the technology of existing manufacture order chain antibody also can be used for producing the single-chain antibody of anti-liver fluke succinodehydrogenase Ip subunit.
The antibody of anti-liver fluke succinodehydrogenase Ip subunit can be used in the immunohistochemistry technology, and distribution and the secretion of liver fluke succinodehydrogenase Ip subunit in polypide that detects in the biopsy specimen drained.
With the also available labelled with radioisotope of liver fluke succinodehydrogenase Ip subunit bonded monoclonal antibody, inject in the body and can follow the tracks of its position and distribution.Antibody among the present invention can be used for preventing or blocking the pathological change that liver fluke succinodehydrogenase Ip subunit causes.
In a fourth aspect of the present invention, suppress the oligonucleotide (comprising sense-rna, antisense DNA, RNA interfering) of liver fluke succinodehydrogenase Ip Subunit mRNA and ribozyme also within the scope of the invention.Ribozyme is the enzyme sample RNA molecule that a kind of energy specificity is decomposed specific RNA, and its mechanism of action is to carry out the endonuclease effect after ribozyme molecule and the hybridization of complementary target RNA-specific.The RNA of antisense and DNA and ribozyme can obtain with existing any RNA or DNA synthetic technology, as the technology widespread use of solid phase phosphoamide chemical synthesis synthetic oligonucleotide.Antisense rna molecule can be transcribed acquisition by the dna sequence dna of this RNA that encodes in external or body.This dna sequence dna has been incorporated into the downstream of rna polymerase promoter of carrier.In order to increase the stability of nucleic acid molecule, available several different methods is modified it, and as increasing the sequence length of both sides, the connection between the ribonucleoside is used phosphoric acid thioester bond or peptide bond but not phosphodiester bond.RNA interfering (iRNA) thus be a class in vivo degrade specifically target gene mRNA make a bit of double stranded rna molecule of this gene silencing, its sequence generally is one section later complementary sequence of mRNA 5 ' downstream 70bp.By this section sequence and reverse sequence thereof being cloned in the same carrier for expression of eukaryon simultaneously transfection China testis polypide or histocyte, the RNA formation dsRNA that this plasmid transcribes out, the iRNA of energy degrade specifically target gene.The mRNA silent technology can be used for treating because the nothing of liver fluke Triptide sulfurtransferase is expressed or cell proliferation, growth or the metabolic disturbance of unusual/non-activity due to expressing, thereby confirms gene (proteinic physiological function).
In a fifth aspect of the present invention, the inhibitor of polypeptide of the present invention and this polypeptide can be directly used in the diagnosis and the treatment of rot.
Specifically with regard to new liver fluke succinodehydrogenase Ip subunit of the present invention, this albumen is the important enzyme of liver fluke energy metabolism, in case enter in the host, can bring out immunne response, can be used as a potential target antigen, is used for the immunodiagnosis of rot.
The present invention also provides SCREENED COMPOUND to check the method for the active medicament of liver fluke succinodehydrogenase Ip subunit with evaluation, succinodehydrogenase Ip subunit is present in the plastosome of liver fluke, in energy metabolism, play a significant role, its antagonist can effectively disturb the liver fluke energy metabolism, cause its metabolism disorder and death, therefore, it can be used as an important drug targets.The antagonist of liver fluke succinodehydrogenase Ip subunit comprises antibody, compound, acceptor disappearance thing and the analogue etc. that filter out.The antagonist of liver fluke succinodehydrogenase Ip subunit can combine and eliminate its function with liver fluke succinodehydrogenase Ip subunit, or suppressing succinodehydrogenase Ip subunit produces, or combines with the avtive spot of succinodehydrogenase Ip subunit and to make this polypeptide can not bring into play biological function.
In screening during as the compound of inhibitor, liver fluke succinodehydrogenase Ip subunit can be added in the bioanalysis mensuration, interactional influence between liver fluke succinodehydrogenase Ip subunit and its substrate be determined whether compound is inhibitor by measuring compound.Can be incorporated into the rondom polypeptide storehouse that solid formation forms by the various amino acid that may make up by screening with liver fluke succinodehydrogenase Ip subunit bonded peptide molecule obtains.During screening, generally tackle liver fluke succinodehydrogenase Ip subunit molecule and carry out mark.
Polypeptide of the present invention also can be used as the peptide spectrum analysis, for example, the polypeptide available physical, chemistry or enzyme carry out the specificity cutting, and carries out the two-dimentional or three-dimensional gel electrophoresis analysis of one dimension, be more preferably and carry out mass spectroscopy.
The polynucleotide of code liver fluke succinate dehydrogenase subunit also can be used for multiple therapeutic purpose.The gene therapy vector of reorganization can be designed for the liver fluke succinodehydrogenase Ip subunit of expressing variation, to suppress endogenic liver fluke succinodehydrogenase Ip subunit activity.For example, a kind of liver fluke succinodehydrogenase Ip subunit of variation can be the liver fluke succinodehydrogenase Ip subunit that shortens, lacked catalytic center, though can combine with the substrate in downstream, lacks succinodehydrogenase Ip subunit activity.Perhaps according to one section little antisense nucleic acid of polynucleotide sequence design of this gene, the translation process after disturbing this gene transcription process and transcribing can play the effect of liver fluke protein metabolism and other physiological function equally.The active plasmid of this inhibition endogenous reorganization succinodehydrogenase Ip subunit can enter in the liver and gall road with suitable formulation and mode, is eaten by liver fluke, enters in its synplasm and works.
The polynucleotide of code liver fluke succinate dehydrogenase subunit can be used for the diagnosis of rot.The polynucleotide of code liver fluke succinate dehydrogenase subunit can be used for detecting the existence of liver fluke and the expression level of succinodehydrogenase Ip subunit.As according to this polynucleotide sequence design primer, from the worm's ovum of stool sample, extract the nucleic acid-templated gene amplification of carrying out with polymerase chain reaction (PCR), whether meet the infection that preset value is determined liver fluke according to the size of the polynucleotide passage that increases.This technology height sensitivity is special, can overcome incidental omission of conventional morphologic detection method and flase drop.The method of gene test not only can detect the infection that whether has liver fluke, and can also carry out somatotype to liver fluke, determines its subspecies or strain.The dna sequence dna of code liver fluke succinate dehydrogenase subunit also can be used for biopsy specimen is hybridized to judge the expression situation of liver fluke succinodehydrogenase Ip subunit.Hybridization technique comprises the Southern blotting, Northern blotting, in situ hybridization etc.These technological methods all are disclosed mature technologies, and relevant test kit all can obtain from commercial channels.Part or all of polynucleotide of the present invention can be used as probe stationary on microarray (Microarray) or DNA chip (being called " gene chip " again), is used for analyzing the differential expression analysis and the gene diagnosis of tissue gene.Carry out the transcription product that RNA-polymerase chain reaction (RT-PCR) amplification in vitro also can detect liver fluke succinodehydrogenase Ip subunit with the special primer of liver fluke succinodehydrogenase Ip subunit.
Sequence of the present invention identifies it also is valuable to karyomit(e).This sequence can be specifically at certain bar China testis karyomit(e) particular location and and can with its hybridization.At present, need to identify the concrete site of each gene on the karyomit(e).Now, have only chromosomal marker thing seldom to can be used for the marker chromosomes position based on actual sequence data (repetition polymorphism).According to the present invention, for these sequences are associated with disease related gene, its important the first step is positioned these dna sequence dnas on the karyomit(e) exactly.
In brief, prepare PCR primer (preferred 15-35bp), sequence can be positioned on the karyomit(e) according to cDNA.Then, these primers are used for the PCR screening and contain each bar China chromosomal somatocyte hybrid cell of testis.Have only those hybrid cells that contain corresponding to the people's gene of primer can produce the fragment of amplification.
The PCR localization method of somatocyte hybrid cell is that DNA is navigated to concrete chromosomal quick method.Use Oligonucleolide primers of the present invention,, can utilize one group to realize inferior location from specific chromosomal fragment or a large amount of genomic clone by similar approach.Other the similar strategy that can be used for chromosomal localization comprises in situ hybridization, uses the karyomit(e) prescreen and the hybridization preliminary election of the airflow classification of mark, thereby makes up the special cDNA storehouse of karyomit(e).
The cDNA clone is carried out fluorescence in situ hybridization (FISH) with Metaphase Chromosome, can in a step, accurately carry out chromosomal localization.In case sequence is positioned to chromosome position accurately, the physical location of this sequence on karyomit(e) just can be associated with the gene map data.
In a sixth aspect of the present invention, the diagnosis of clonorchiasis sinensis is except the Pathogen Biology inspection except routine, and main mode is to use the immunological diagnostic reagent box.Mainly contain two classes: enzyme linked immunological kit (ELISA) and tachysynthesis colloidal gold kit (ICT).The diagnosis of clonorchiasis sinensis can be judged existing disease infection by the circulating antigen that detects in serum or the urine, also can come rapid screening by the specific antibody that detects in serum or the saliva.Because clonorchis sinensis mainly is to colonize in outside the tissue, the antigenic component overwhelming majority that is produced has only the infectiosity height along with bile enters enteron aisle, and polypide is serious to bile duct obstruction, when causing the epithelial duct serious damage, its secretion movement just can enter in liver and the peripheral blood.The circulating antigen major part that enters in the peripheral blood is neutralized by antibody, has only the circulating antigen of small-amount free to be detected.Therefore, can reflect existing disease infection though detect the method for circulating antigen, susceptibility is lower.It is at present, clinical that what be used for auxiliary diagnosis mainly is antibody assay kit.The method that detects antibody is divided into two kinds, and the one, catch to such an extent that antibody combines as detection reagent with the antigen on being coated on Sptting plate or reaction film with mark two is anti-, a kind of is that the antigen of usefulness mark is as detection reagent.Two is anti-as detection reagent, generally can only detect a kind of antibody, and non-specific binding is than higher; Labelled antigen can detect multiple antibody as detection reagent, and specificity is higher.
The present invention can utilize the liver fluke succinodehydrogenase Ip subunit of purifying to prepare the ELISA detection kit, also can utilize the liver fluke succinodehydrogenase Ip subunit of purifying to prepare the colloidal gold immunochromatographiassay assay reagent box.
In a seventh aspect of the present invention, clonorchis sinensis is to organize epizoa, and immunity system is difficult to directly and its effect.It is its main aversion response that the antigenic stimulation body mucous membrane system that it produces produces mucosal immunoreaction.The secretory IgA that mucosal immunity produces can stop secretion to drain antigen and enter liver cell by epithelial duct, thereby reduce the toxic action of these antigenic components to body, rather than directly polypide be played the effect that kills and wounds of attacking.Therefore, the vaccine of clonorchis sinensis is based on the oral type vaccine, and the succinodehydrogenase Ip protein subunit of will recombinating mixes with Yelkin TTS at 1: 10, the normal saline solution that adds 10 times, liposome is made in ultrasonic concussion, the slow releasing capsule of packing into is made the oral type recombinant protein vaccine.
Description of drawings
Fig. 1 is the polyacrylamide gel electrophoresis figure (SDS-PAGE) of isolating liver fluke succinodehydrogenase Ip subunit, and 37.6kDa is proteinic molecular weight, and the arrow indication is isolated protein band.
Fig. 2 is the colloidal gold immunochromatographimethod mode chart
Label
1 testing wire, 2 nature controlling lines, 3 glass fiber sheets
Embodiment
Below in conjunction with specific embodiment, further set forth the present invention.Should be understood that these embodiment only to be used to the present invention is described and be not used in and limit the scope of the invention.The experimental technique of unreceipted actual conditions in the following example, usually according to people such as normal condition such as Sambrook, molecular cloning: laboratory manual (New York:Cold Spring Harbor Laboratory Press, 1989) condition described in, or the condition of advising according to manufacturer.
Embodiment 1: the clone of liver fluke succinodehydrogenase Ip subunit
Extract the total RNA of liver fluke adult with guanidinium isothiocyanate/phenol/chloroform single stage method.From total RNA, separate poly (A) mRNA with Quik mRNA Isolation Kit (Qiegene company product).2ug poly (A) mRNA forms cDNA through reverse transcription.CDNA fragment orientation is inserted on the multiple clone site of pBSK (+) carrier (Clontech company product) with Smart cDNA clone's test kit (available from Clontech), transforms DH5 α, bacterium forms the cDNA library.Measure the sequence of all clones' 5 ' and 3 ' end with Dye terminate cycle reactionsequencing kit (Perkin-Elmer company product) and ABI 377 automatic sequencers (Perkin-Elmer company).CDNA sequence and the existing public dna sequence data storehouse (Genebank) measured are compared, found that the cDNA sequence of one of them clone 1G10 is new DNA.By synthetic a series of primers the contained insertion cDNA fragment of this clone is carried out two-way mensuration.The result shows, the contained full-length cDNA of 1G10 clone is 1011bp (shown in SeqID NO:1), from 47bp to 880bp the open reading frame (ORF) of a 981bp, the new protein (shown in Seq ID NO:2) of encoding arranged.We are with this clone's called after pBS-c001g10, encoded protein matter called after liver fluke succinodehydrogenase Ip subunit.
Embodiment 2:cDNA clone's homology retrieval
With the sequence and the encoded protein sequence thereof of liver fluke succinodehydrogenase Ip subunit of the present invention, with Blast program (Basiclocal Alignment search tool) [Altschul, SF et al.J.Mol.Biol.1990; 215:403-10], carry out the homology retrieval at databases such as Genbank, Swissport.The gene the highest with peptides homologous of the present invention is a kind of known people's succinodehydrogenase Ip subunit, number is XP_216558.1 in the access of Genbank.The result shows both height homologies, and its homogeny is 72%; Similarity is 83%.
Embodiment 3: with the gene of RT-PCR method clones coding liver fluke succinodehydrogenase Ip subunit
Propping up the total RNA of testis adult with China is template, is that primer carries out the synthetic cDNA of reverse transcription reaction with oligo-dT, with behind the test kit purifying of Qiagene, carries out pcr amplification with following primer:
Primer1：5’-GGGGATATATGCAAGGTTTCGTTT-3’ (SEQ?ID?NO：3)
Primer2：5’-TTTTTGTTGATGAAAAAGCTGAAAGT-3’ (SEQ?ID?NO：4)
Primer1 is the forward sequence that begins of 1bp that is positioned at the 5 ' end of SEQ ID NO:1;
Primer2 be SEQ ID NO:1 in 3 ' end reverse sequence.
The condition of amplified reaction: in the reaction volume of 50 μ l, contain 50mmol/L KCl, 10mmol/LTris-Cl, (pH8.5), 1.5mmol/L MgCl
2, 200 μ mol/L dNTP, 10pmol primer, the Taq archaeal dna polymerase of 1U (Clontech company product).Go up by 25 cycles of following conditioned response at PE9600 type DNA thermal cycler (Perkin-Elmer company): 94 ℃ of 30sec; 55 ℃ of 30sec; 72 ℃ of 2min.When RT-PCR, establish the blank negative contrast of positive contrast of β-actin and template simultaneously.Amplified production is connected to (Invitrogen company product) on the pCR carrier with the test kit purifying of QIAGEN company with TA clone test kit.The dna sequence analysis result shows that the dna sequence dna of PCR product and the 1-1011bp shown in the SEQ ID NO:1 are identical.
Embodiment 4:Northern blotting is analyzed the expression of liver fluke succinodehydrogenase Ip subunit gene:
Extract total RNA[Anal.Biochem 1987,162,156-159 with single stage method].This method comprises acid guanidine thiocyanate phenol-chloroform extracting.Promptly use 4M guanidinium isothiocyanate-25mM Trisodium Citrate, 0.2M sodium acetate (pH4.0) carries out homogenate to tissue, adds the phenol of 1 times of volume and the chloroform-primary isoamyl alcohol (49: 1) of 1/5 volume, and is centrifugal after mixing.The sucking-off aqueous phase layer adds Virahol (0.8 volume) and with the centrifugal RNA precipitation that obtains of mixture.With RNA precipitation 70% washing with alcohol that obtains, dry and soluble in water.With 20 μ g RNA, on 1.2% sepharose that contains 20mM 3-(N-morpholino) propanesulfonic acid (pH7.0)-5mM sodium acetate-1mM EDTA-2.2M formaldehyde, carry out electrophoresis.Be transferred on the nitrocellulose filter then.With α-
32P dATP prepares by random priming
32The dna probe of P-mark.Used dna probe is the liver fluke succinodehydrogenase Ip subunit coding region sequence (47bp to 880bp) of pcr amplification shown in Figure 1.Probe (about 2 * 10 with the 32P-mark
6Cpm/ml) spend the night in 42 ℃ of hybridization in a solution with the nitrocellulose filter that has shifted RNA, this solution comprises 50% methane amide-25mM KH
2PO
4(pH7.4)-5 * SSC-5 * Denhardt ' s solution and 200 μ g/ml salmon sperm DNAs.After the hybridization, filter membrane is washed 30min in 55 ℃ in 1 * SSC-0.1%SDS.Then, analyze with quantitative with Phosphor Imager.
Embodiment 5: vivoexpression, separation and the purifying of reorganization liver fluke succinodehydrogenase Ip subunit
According to SEQ ID NO:1 and coding region sequence shown in Figure 1, design a pair of specificity amplification primer, sequence is as follows:
Primer3：5’-CCCCATATGATGTCGAATTCGGTGATCACGCGTTTG-3’ (Seq?ID?No：5)
Primer4：5’-CATGGATCCTTATACTGTGGCCGTTGATGGCTTTTT-3’ (Seq?ID?No：6)
5 ' end of these two sections primers contains BamHI and HindIII restriction enzyme site respectively, be respectively the encoding sequence of target gene 5 ' end and 3 ' end thereafter, NdeI and BamHI restriction enzyme site are corresponding to expression vector plasmid pET-30a (+) (Novagen company product, Cat.No.69865.3) the selectivity restriction enzyme site on.With the pBS-CS1G10 plasmid that contains the total length goal gene is template, carries out the PCR reaction.The PCR reaction conditions is: contain pBS-CS1G10 plasmid 10pg, primer Primer-3 and Primer-4 among the cumulative volume 50 μ l and be respectively 10pmol, Advantage polymerase Mix (Clontech company product) 1 μ l.Loop parameter: 94 ℃ of 20s, 63 ℃ of 30s, 68 ℃ of 2 min, totally 25 circulations.Respectively amplified production and plasmid pET-30a (+) are carried out double digestion with EcoRI and BamHI, reclaim big fragment respectively, and connect with the T4 ligase enzyme.Connect product and transform, after the dull and stereotyped overnight incubation of the LB that contains kantlex (final concentration 30 μ g/ml), use the colony polymerase chain reaction (PCR) method screening positive clone, and check order with the big enterobacterial DH5 of Calcium Chloride Method α.Select the correct positive colony of sequence (pET-CS1G10) with Calcium Chloride Method with recombinant plasmid transformed e. coli bl21 (DE3) plySs (Novagen company product).In the LB liquid nutrient medium that contains kantlex (final concentration 30 μ g/ml), host bacterium BL21 (pET-CS1G10) is cultured to logarithmic phase at 37 ℃, adds IPTG to final concentration 1mmol/L, continues to cultivate 5 hours.Centrifugal collection thalline, through the broken bacterium of ultrasonic wave, centrifugal collection supernatant with carrying out chromatography with 6 Histidines (6His-Tag) bonded affinity column His.Bind Quick Cartridge (Novagen company product), has obtained the target protein liver fluke succinodehydrogenase Ip subunit of purifying.Through the SDS-PAGE electrophoresis, obtain a single band (Fig. 1) at the 37.6kDa place.This band is transferred on the pvdf membrane carries out the n terminal amino acid sequential analysis with the Edams hydrolysis method, 15 amino acid of N-end hold 15 amino-acid residues identical with the N-shown in the SEQ ID NO:2 as a result.
The physicochemical property of embodiment 6 liver fluke succinodehydrogenase Ip subunits
With the liver fluke succinodehydrogenase Ip subunit of affinitive layer purification, after enterokinase enzyme excision carrier sequence,, record its molecular weight and be about 32kDa through SDS-PAGE electrophoresis and standard molecule discharge curve; Contain 29 of acidic amino acid residues, 37 of alkaline amino acid residues utilize Amerham isoelectric focusing electrophoresis instrument, and through the isoelectric focusing electrophoresis of pH3-10 and pH7-10 gradient fixing glue, recording its iso-electric point is 8.76.Protein molecular is spherical in aqueous environment, its transformation period is 30 hours in the Mammals plastosome, greater than 20 hours, surpasses 10 hours in intestinal bacteria, the less stable of protein structure at yeast cell.
The generation of embodiment 7 anti-liver fluke succinodehydrogenase Ip subunit antibodies
With adding the complete Freund's adjuvant immunizing rabbit, add the incomplete Freund's adjuvant booster immunization once with this albumen again after 15 days through the liver fluke succinodehydrogenase Ip of affinitive layer purification subunit.Employing is through 15 μ g/ml reorganization liver fluke succinodehydrogenase Ip subunit
Add the complete Freund's adjuvant immunizing rabbit, add the incomplete Freund's adjuvant booster immunization once with reorganization liver fluke succinodehydrogenase Ip subunit again after 15 days.Employing is done the titre that ELISA measures antibody in the rabbit anteserum through the titer plate of 15 μ g/ml reorganization liver fluke succinodehydrogenase Ip subunit bag quilt.From the rabbit anteserum of antibody positive, separate total IgG with albumin A-Sepharose.Polypeptide is incorporated on the Sepharose4B post of cyanogen bromide-activated, from total IgG, separates anti-peptide antibody with affinity chromatography.Immuno-precipitation proof antibody purified can combine with liver fluke succinodehydrogenase Ip subunit specifically, and this antibody is polyclonal antibody, and tiring of the two expansion tests of agarose is 1: 32.Tire more than 1: 16 with the reaction of polypide crude antigen.This antibody can detect the liver fluke patient's of severe infection serum lactic dehydrogenase circulating antigen.
Embodiment 8: polynucleotide passage of the present invention is as the application of hybridization probe
Picking out suitable oligonucleotide fragment from polynucleotide of the present invention is of use in many ways as hybridization probe, as can whether containing polynucleotide sequence of the present invention and detect the homologous polynucleotide sequence to identify it with the healthy tissues of different sources or the genome or the hybridization of cDNA library of pathological tissue with this probe, whether further also available this probe in detecting polynucleotide sequence of the present invention or the expression of its homologous polynucleotide sequence in healthy tissues or pathological tissue cell be unusual.Select oligonucleotide fragment as hybridization probe from polynucleotide SEQ ID NO:1 of the present invention, the several aspects that should follow following principle and need to consider: the probe size preferable range is a 18-50 Nucleotide; GC content is 30%-70%, and surpassing then, non-specific hybridization increases; Probe interior should not have complementary region; What meet above condition can be used as the primary election probe, further do the computer sequential analysis then, comprise this primary election probe is carried out homology relatively with its source sequence area (being SEQ ID NO:1) and other known genome sequence and complementary district thereof respectively, if with the homology in non-target molecule zone greater than 85% or there are 15 continuous bases of surpassing identical, then this primary election probe is general just should not use; In addition, again according to the probe fragment that designed or its complementary segmental replacement mutant nucleotide sequence as second probe.
Probe 1 (probe1) belongs to first kind probe, and complete homology of gene fragment or the complementation (40Nt) of SEQ ID NO:1:
5’-ATAAAGATTAAGAATGAACAAGATCCCACGCTCACTTTTC-3’ (Seq?ID?No：7)
Probe 2 (probe2) belongs to the second class probe, is equivalent to gene fragment or its complementary segmental replacement mutant nucleotide sequence (40Nt) of SEQ ID NO:1:
5’-ATAAAGATTAAGAATGGACAAGATCCCACGCTCACTTTTC-3’ (Seq?ID?No：8)
Nucleic acid probe adopts the filter hybridization method usually, comprises dot blotting, Southern blotting, Northern blotting and copy method etc., and they all are that polynucleotide sample to be measured is fixed on use essentially identical step crossover in back on the filter membrane.
Other unlisted common agents and the compound method thereof relevant with following concrete experimental procedure please refer to document: DNAPROBES G.H.Keller; M.M.Manak; Stockton Press, 1989 (USA) and molecular cloning laboratory manual books more commonly used are as works such as " molecular cloning experiment guide " (second edition in 1998) [U.S.] Sa nurse Brooker, Science Press.
Step: 1) fresh or fresh liver fluke of thawing is used cooled homogenate damping fluid (0.25mol/L sucrose; 25mmol/LTris-HCl, pH7.5; 25mmol/LnaCl; 25mmol/L MgCl
2) precipitation that suspends (approximately 10ml/g), 4 ℃ with electric homogenizer homogenate tissue suspension at full speed, until tissue by broken fully.DNA with in the phenol extraction process tissue uses ethanol sedimentation then.In the time of must removing RNA and pollute, RNA enzyme A can be added in the dna solution, final concentration is 100ug/ml, 37 ℃ of insulations digestion in 30 minutes RNA, and then extracting DNA again.The preparation of sample film:
2) get 4 * 2 suitably nitrocellulose filters (NC film) of size, mark point sample position and sample number thereon gently with pencil, each probe needs two NC films, so that wash film with high strength condition and strength condition respectively in the experimental procedure of back.Draw and each 15 microlitre of contrast, put on the sample film, dry at room temperature.Placing to soak into has 0.1mol/LNaOH, and last 5 minute of filter paper (twice) of 1.5mol/LNaCl, drying to place to soak into has 0.5mol/L Tris-HCl (pH7.0), last 5 minute of filter paper (twice) of 3mol/LNaCl, dries.Be sandwiched in the clean filter paper, wrap, 60-80 ℃ of vacuum-drying 2 hours with aluminium foil.
3) probe phosphokinase mark
32Cross Sephadex G-50 post behind the P, monitor isotopic weight, merge and be required preparation behind the collection liquid of first peak with liquid glimmer instrument
32P-Probe (second peak for free γ-
32P-dATP).
4) prehybridization: the sample film is placed plastics bag, adding 3-10mg prehybridization solution (10 * Denhardt ' s; 6 * SSC, 0.1mg/ml CT DNA (calf thymus DNA).), seal sack after, 68 ℃ of water-baths were shaken 2 hours.
5) hybridization: plastics bag is cut off one jiao, adds the probe prepare, seal sack after, 42 ℃ of water-baths are shaken and are spent the night.
6) wash film:
High strength is washed film:
Take out and hybridized good sample film; 2 * SSC among the 0.1%SDS, washes 15 minutes (2 times) for 40 ℃; 0.1 * SSC among the 0.1%SDS, washes 15 minutes (2 times) for 40 ℃; 0.1 * SSC among the 0.1%SDS, washes 30 minutes (2 times) for 55 ℃, room temperature is dried.
Low strength is washed film:
Take out and hybridized good sample film; 2 * SSC among the 0.1%SDS, washes 15 minutes (2 times) for 37 ℃; 0.1 * SSC among the 0.1%SDS, washes 15 minutes (2 times) for 37 ℃; 0.1 * SSC among the 0.1%SDS, washes 15 minutes (2 times) for 40 ℃, room temperature is dried.
7) X-light autography:
-70 ℃, X-light autography (the compressing tablet time decides according to hybridization spot radioactivity is strong and weak).
Experimental result:
Adopt low strength to wash the hybrid experiment that the film condition is carried out, more than four strong and weak not obviously differences of probe hybridization spot radioactivity; And adopting low strength to wash the hybrid experiment that the film condition is carried out, the hybridization spot radioactive intensity of probe 1 obviously is better than the radioactive intensity of other three probe hybridization spots.Thereby available probe 1 is qualitative and analyze existence and the differential expression of polynucleotide of the present invention in different tissues quantitatively.
Embodiment 9: the preparation diagnostic kit
The preparation of ELISA detection kit: the liver fluke succinodehydrogenase Ip subunit of purifying is cushioned liquid with the carbonate bag, and ((pH9.6) is made into 0.1mg/ml, every hole as the 96 hole enzyme marks adds 50ul, 4 ℃ are spent the night, after outwelling coating buffer, with the unnecessary protein binding site of PBS-Tween20 solution 100ul sealing hole wall that contains 10% skim-milk, after spending the night, 4 ℃ of sealings outwell confining liquid.Add test serum 50ul in the enzyme plate reacting hole, jog is after 5 minutes, leaves standstill in 37 ℃ of wet boxes 30～60 minutes, shakes repeatedly with the PBS-Tween20 washings and washs each 3 minutes 3 times; Add the goat anti-human igg (1: 1000 diluent 50ul) of horseradish peroxidase or alkali phosphatase enzyme mark again, repeat above-mentioned combination and washing process, add substrate and chromogenic reagent then, when the appearance colour developing is obvious, add 2% sulphuric acid soln termination reaction.Visual inspection or with microplate reader assaying reaction result.
The preparation of colloidal gold immunochromatographiassay assay reagent box: there are three kinds of the bar of soaking formula (dipstick), card form and boxlikes in common immunochromatography system.They have identical ultimate principle and structure shown in Figure 2: by chromatographic system (chromatographic film links to each other with one or two absorption layer) solid-phase immunity reactive system (antigen or antibody are wire and are coated on the chromatographic film certain location as testing wire or nature controlling line), sample and colloid gold label reagent add from an end, under the capillary action of film, move to the other end along the film surface, and be absorbed by the absorption layer.Immune association reaction takes place with the capture agent that is combined on the film in composition to be measured in the sample and gold-immunochromatographyreagent reagent for assay in the chromatography process, and rests on bag by on the line (comprising testing wire 1 and nature controlling line 2), demonstrates the response line of a redness.In sample, do not contain composition to be measured, then do not develop the color at testing wire 1 place, then apparent red as the nature controlling line 2 of positive control.Soaking bar formula detection kit successively adds the test strip lower end in the colloidal gold solution of analyte sample fluid and mark; In card form and the boxlike detection kit, the Radioactive colloidal gold of mark is with on the exsiccant solid form preservation glass fiber sheets 3 at one end, card form only needs solution to be measured and damping fluid directly are added drop-wise on the glass fiber sheets, the card that closes, viewing window judged result that can capping behind the several minutes; Boxlike is packed detector bar in the small plastic box, puts the corresponding circular well of an end of Radioactive colloidal gold, and sample and damping fluid add from well, behind the several minutes from rectangular viewing window judged result.
In this detection kit, chromatographic film is the cellulose mixture film of aperture 8 μ m, the liver fluke serum lactic dehydrogenase of purifying is coated on the far-end of absorption layer as detection line, a China testis patient's positive serum is coated on the near-end of absorption layer as nature controlling line, the colloidal gold solution of mark liver fluke liver fluke succinodehydrogenase Ip subunit is added drop-wise to the glass fiber sheets after drying, is placed on the other end of chromatographic film.
The preparation of Radioactive colloidal gold and mark: chlor(o)aurate is made into 0.01% concentration with deionized ultrapure water, after boiling, the citric acid three sodium solution of rapid adding 1%, (every 100ml adds 2ml), not from the rapid jolting mixing of fire, boil solution colour always and become the red recession fire of grape wine, supply original volume with ultrapure water.The about 20nm of median size of the Radioactive colloidal gold of preparation.The colloidal gold solution for preparing is transferred pH9.0 with the solution of potassium carbonate of 0.25mol/L, the liver fluke succinodehydrogenase Ip subunit that under stirring state, adds purifying by the amount of 15 μ g/mL, reacted 10 minutes, centrifugal 30 minutes of the centrifugal force of 15000g, precipitation suspends again with the PBS (pH9.5) of original volume 1/10.
Embodiment 10: the preparation vaccine
Liver fluke is to organize epizoa, and immunity system is difficult to directly and its effect.It is its main aversion response that the antigenic stimulation body mucous membrane system that it produces produces mucosal immunoreaction.The secretory IgA that mucosal immunity produces can stop secretion to drain antigen and enter liver cell by epithelial duct, thereby reduce the toxic action of these antigenic components to body, rather than directly polypide be played the effect that kills and wounds of attacking.Therefore, the vaccine of liver fluke is based on the oral type vaccine, and the liver fluke succinodehydrogenase Ip subunit of will recombinating mixes with Yelkin TTS at 1: 10, the normal saline solution that adds 10 times, liposome is made in ultrasonic concussion, the slow releasing capsule of packing into is made the oral type recombinant protein vaccine.
Sequence table
＜110〉Zhongshan University
＜120〉liver fluke succinodehydrogenase Ip subunit, its coding nucleic acid and application thereof
<130>cs0011G10
<160>8
<170>PatentIn?version?3.1
<210>1
<211>1011
<212>DNA
<213>Clonorchis?sinensis
<400>1
ggggatatat?gcaaggtttc?gttttggtcg?gctgcctaca?attactatgt?cgaattcggt 60
gatcacgcgt?ttggctccgg?tgttttccat?ggtacgccat?gcgtcaactg?ctgcggcaac 120
agctccccga?atgaaaacgt?tttccgttta?tcgatggaac?ccagacaaac?ccggggagaa 180
gccatatatg?aaagattata?aagtcgacct?gaacgagtgt?gggcccatgg?tcctcgatgc 240
gttgataaag?attaagaatg?aacaagatcc?cacgctcact?tttcgtcgtt?cgtgccgcga 300
aggcatttgt?ggctcatgtg?ctatgaacat?cgccggtcgt?aaccatttgg?cttgtttgtg 360
ggaaattgac?caagatctga?acaagccgac?gaagatctat?ccgctcccgc?atatgtttgt 420
catcaaagat?ctcgtcccgg?atatgaacaa?cttctacgca?cagtatcgct?ggatcgagcc 480
atacttgaag?aagaagggtg?tgtctgaaga?ggatattggg?aaagccactt?actatcagtc 540
ggttgaggat?cgggcaaagc?tggatggtct?gtatgagtgc?attttgtgcg?cttgttgtgc 600
cacatcatgt?ccttcatact?ggtggaacgg?agacaagtat?cttggaccgg?cggtcttgtt 660
acaagcatac?cgctggctca?tcgattcaag?agatgactac?acgtacgagc?gtttgacaca 720
gtttcagaac?aaatggtcac?tgtaccggtg?ccacactatc?atgaactgca?ccgaaacttg 780
ccctaaaggt?ctcaatcccg?gtctggctat?tggtgaaatc?aagaaaatgc?tcatctacta 840
caaccaatac?aaaaacaaaa?agccatcaac?ggccacagta?taatagattt?gcaatctcgc 900
tggtagagcg?gaattgttta?tagtgaccaa?aattcattaa?gatgtttgtt?tatcttcatc 960
cggtctaaac?ggacaccaat?aataaacttt?cagctttttc?atcaacaaaa?a 1011
<210>2
<211>278
<212>PRT
<213>Clonorchis?sinensis
<400>2
Met?Ser?Asn?Ser?Val?Ile?Thr?Arg?Leu?Ala?Pro?Val?Phe?Ser?Met?Val
1 5 10 15
Arg?His?Ala?Ser?Thr?Ala?Ala?Ala?Thr?Ala?Pro?Arg?Met?Lys?Thr?Phe
20 25 30
Ser?Val?Tyr?Arg?Trp?Asn?Pro?Asp?Lys?Pro?Gly?Glu?Lys?Pro?Tyr?Met
35 40 45
Lys?Asp?Tyr?Lys?Val?Asp?Leu?Asn?Glu?Cys?Gly?Pro?Met?Val?Leu?Asp
50 55 60
Ala?Leu?Ile?Lys?Ile?Lys?Asn?Glu?Gln?Asp?Pro?Thr?Leu?Thr?Phe?Arg
65 70 75 80
Arg?Ser?Cys?Arg?Glu?Gly?Ile?Cys?Gly?Ser?Cys?Ala?Met?Asn?Ile?Ala
85 90 95
Gly?Arg?Asn?His?Leu?Ala?Cys?Leu?Trp?Glu?Ile?Asp?Gln?Asp?Leu?Asn
100 105 110
Lys?Pro?Thr?Lys?Ile?Tyr?Pro?Leu?Pro?His?Met?Phe?Val?Ile?Lys?Asp
115 120 125
Leu?Val?Pro?Asp?Met?Asn?Asn?Phe?Tyr?Ala?Gln?Tyr?Arg?Trp?Ile?Glu
130 135 140
Pro?Tyr?Leu?Lys?Lys?Lys?Gly?Val?Ser?Glu?Glu?Asp?Ile?Gly?Lys?Ala
145 150 155 160
Thr?Tyr?Tyr?Gln?Ser?Val?Glu?Asp?Arg?Ala?Lys?Leu?Asp?Gly?Leu?Tyr
165 170 175
Glu?Cys?Ile?Leu?Cys?Ala?Cys?Cys?Ala?Thr?Ser?Cys?Pro?Ser?Tyr?Trp
180 185 190
Trp?Asn?Gly?Asp?Lys?Tyr?Leu?Gly?Pro?Ala?Val?Leu?Leu?Gln?Ala?Tyr
195 200 205
Arg?Trp?Leu?Ile?Asp?Ser?Arg?Asp?Asp?Tyr?Thr?Tyr?Glu?Arg?Leu?Thr
210 215 220
Gln?Phe?Gln?Asn?Lys?Trp?Ser?Leu?Tyr?Arg?Cys?His?Thr?Ile?Met?Asn
225 230 235 240
Cys?Thr?Glu?Thr?Cys?Pro?Lys?Gly?Leu?Asn?Pro?Gly?Leu?Ala?Ile?Gly
245 250 255
Glu?Ile?Lys?Lys?Met?Leu?Ile?Tyr?Tyr?Asn?Gln?Tyr?Lys?Asn?Lys?Lys
260 265 270
Pro?Ser?Thr?Ala?Thr?Val
275
<210>3
<211>24
<212>DNA
<213>Clonorchis?sinensis
<400>3
ggggatatat?gcaaggtttc?gttt 24
<210>4
<211>26
<212>DNA
<213>Clonorchis?sinensis
<400>4
tttttgttga?tgaaaaagct?gaaagt 26
<210>5
<211>36
<212>DNA
<213>Clonorchis?sinensis
<400>5
ccccatatga?tgtcgaattc?ggtgatcacg?cgtttg 36
<210>6
<211>36
<212>DNA
<213>Clonorchis?sinensis
<400>6
catggatcct?tatactgtgg?ccgttgatgg?cttttt 36
<210>7
<211>40
<212>DNA
<213>Clonorchis?sinensis
<400>7
ataaagatta?agaatgaaca?agatcccacg?ctcacttttc 40
<210>8
<211>40
<212>DNA
<213>Clonorchis?sinensis
<400>8
ataaagatta?agaatggaca?agatcccacg?ctcacttttc 40
Claims (9)
1, a kind of isolated polypeptide-liver fluke succinodehydrogenase Ip subunit is characterized in that it includes: the polypeptide of the aminoacid sequence shown in the SEQ ID NO:2 or active fragments, analogue or the derivative of its polypeptide.
2, a kind of isolating polynucleotide, it is characterized in that described polynucleotide comprise be selected from down the group in a kind of:
(a) coding has the polynucleotide of the polypeptide of aminoacid sequence shown in the SEQ ID NO:2 or its fragment, analogue, derivative;
(b) with polynucleotide (a) complementary polynucleotide.
3, polynucleotide as claimed in claim 2, the sequence that it is characterized in that described polynucleotide include the sequence of 1-1011 position among the sequence of 47-880 position among the SEQ ID NO:1 or the SEQ ID NO:1.
4, a kind of can with polypeptide bonded antibody, it is characterized in that described antibody be can with described liver fluke succinodehydrogenase Ip subunit specificity bonded antibody.
5, a class is regulated the polynucleotide of expression of polypeptides, it is characterized in that they are the polynucleotide that suppress the expression of described liver fluke succinodehydrogenase Ip subunit, and have the polynucleotide sequence shown in the SEQ ID NO:1 or its segmental antisense sequences or the oligomerization double-stranded RNA consistent with its sequence.
6, the application of polypeptide according to claim 1 is characterized in that it is applied to screen the inhibitor of liver fluke succinodehydrogenase Ip subunit; Perhaps be used for the peptide finger print identification.
7, as the application of the described polynucleotide of arbitrary claim among the claim 2-3, it is characterized in that it is used for nucleic acid amplification reaction as primer, perhaps be used for hybridization, perhaps be used to make gene chip or microarray as probe.
8, a kind of test kit that detects liver fluke is characterized in that it contains arbitrary or its combination of the described antibody of primer, claim 4, the described polypeptide of claim 1 of specific detection liver fluke succinodehydrogenase Ip subunit.
9, a kind of vaccine that is used to prevent rot is characterized in that it contains the described polypeptide of claim 1 or contains claim 2 or the carrier for expression of eukaryon of 3 described polynucleotide.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN 200510024006 CN1670201A (en) | 2005-02-22 | 2005-02-22 | Fumaric reductase Ip subunit of liver fluke, its coding acid and application |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN 200510024006 CN1670201A (en) | 2005-02-22 | 2005-02-22 | Fumaric reductase Ip subunit of liver fluke, its coding acid and application |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CN1670201A true CN1670201A (en) | 2005-09-21 |
Family
ID=35041638
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN 200510024006 Pending CN1670201A (en) | 2005-02-22 | 2005-02-22 | Fumaric reductase Ip subunit of liver fluke, its coding acid and application |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN1670201A (en) |
Cited By (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN112029845A (en) * | 2020-08-14 | 2020-12-04 | 桂林医学院 | Application of 5-HTR7 gene and expression product thereof as target in preparation of anti-liver fluke infection product |
-
2005
- 2005-02-22 CN CN 200510024006 patent/CN1670201A/en active Pending
Cited By (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN112029845A (en) * | 2020-08-14 | 2020-12-04 | 桂林医学院 | Application of 5-HTR7 gene and expression product thereof as target in preparation of anti-liver fluke infection product |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN1683403A (en) | Japanese blood fluke cell periodic static agent, its coded nucleic acid and its use | |
| CN1670194A (en) | Calcineurin of clonorchis sinensis, its coding nucleic acid and application | |
| CN1670198A (en) | Thermostable type cytoplasm malic dehydrogenase of clonorchis sinensis, its coding nucleic acid and application | |
| CN1670201A (en) | Fumaric reductase Ip subunit of liver fluke, its coding acid and application | |
| CN1683405A (en) | Clonorichis sinensis II 14-3-3 protein, its coded nucleic acid and its use | |
| CN1670199A (en) | I type aldehyde dehydrogenase of clonorchis sinensis, its coding nucleic acid and application | |
| CN1670195A (en) | Propionyl-CoA carboxylase of clonorchis sinensis, its coding nucleic acid and application thereof | |
| CN1683402A (en) | Clonorichis sinensis annexin, its coded nucleic acid and its use | |
| CN1670197A (en) | Arginase of Japanese blood fluke, its coding nucleic acid and application | |
| CN1670202A (en) | Microsome GST-1 of clonorchis sinensis, its coding acid and application | |
| CN1683404A (en) | Clonorichis sinensis ubiquitin homogenetic protein, its coded nucleic acid and its use | |
| CN1670204A (en) | Autolytic enzyme of streptococcus pneumoniae, its coding nucleic acid and application | |
| CN1683406A (en) | Clonorichis sinensis CDC 42 like protein, its coded nucleic acid and its use | |
| CN1670196A (en) | Adenylate kinase 3 of clonorchis sinensis, its coding nucleic acid and application | |
| CN1670205A (en) | Protease subunit C3 of clonorchis sinensis, its coding nucleic acid and application | |
| CN1683401A (en) | Clonorchis sinensis GTP bindin alpha subunit, its coded nucleic acid and its use | |
| CN1670206A (en) | Protease subunit C7-I of clonorchis sinensis, its coding nucleic acid and application | |
| CN1670200A (en) | Lactate dehydrogenase of clonorchis sinensis, its coding nucleic acid and application | |
| CN1324831A (en) | New polypeptide human non-insulin dependent diabetes related protein 25 and polynucleotides for encoding same | |
| CN1333245A (en) | Novel polypeptide--human nucleoporin p54-16.61 and polynucleotide for encoding said polypeptide | |
| CN1683400A (en) | Clonorchis sinensis transport protein, its coded nucleic acid and its use | |
| CN1342686A (en) | Polypeptide-human kidney-specific protein 35.53 and polynucleotide for cocing it | |
| CN1311205A (en) | New polypeptide-human micronucleus protein 9 and polynucleotide for coding said polypeptide | |
| CN1311202A (en) | New polypeptide-human reverse transcription relative factor 22 and polynucleotide for coding said polypeptide | |
| CN1311329A (en) | New polypeptide-human phosphomannose isomerase 16 and polynucleotide for coding such polypeptide |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| C06 | Publication | ||
| PB01 | Publication | ||
| C10 | Entry into substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| C02 | Deemed withdrawal of patent application after publication (patent law 2001) | ||
| WD01 | Invention patent application deemed withdrawn after publication |